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 ABSTRACT 
The secretory pathway defines and maintains the intracellular architecture of the eukaryotic 
cell. Proteins targeted to either the plasma membrane, the extracellular medium or to specific 
organelles within the cell are dependent on the correct transfer along this pathway. The 
importance of its function has become increasingly clear and several proteins in this pathway 
have been linked to human diseases. One disease that is genetically associated with transport 
processes in the early secretory pathway is the combined blood coagulation factor V and VIII 
deficiency (F5F8D). It has been established that F5F8D is caused by mutations in the genes 
that code for the membrane bound glycoprotein receptor ERGIC-53 or its co-receptor protein 
MCFD2. Together these two proteins form a calcium dependent complex with 1:1 
stoichiometry that specifically interacts and assist transport of the glycosylated blood 
coagulation proteins FV and FVIII from the endoplasmic reticulum.  
In this thesis, NMR-spectroscopy and X-ray crystallography have been applied in order to 
clarify the organisation of the ERGIC-53/MCFD2 glycoprotein transport receptor complex. 
The work resulted in the three-dimensional structure of MCFD2 in solution determined by 
NMR and the crystal structure of MCFD2 in complex with the carbohydrate recognition 
domain of ERGIC-53. These structures gave a first molecular view of the organisation of a 
cargo receptor complex in the early secretory pathway and revealed that MCFD2 undergoes 
significant conformational changes upon complex formation. 
  
NMR and CD-spectroscopy analysis showed MCFD2 to be disordered in the absence of Ca2+ 
ions, but to adopt a predominantly ordered structure upon binding Ca2+ ions. Hence, these data 
suggest that calcium binding and consequent folding of MCFD2 to be the underlying 
mechanism for the previously observed calcium dependence of the MCFD2/ERGIC-53 
interaction. Moreover, the consequences of all known F5F8D causing missense mutations 
found in MCFD2 could be explained at a molecular level. The results highlight the importance 
of intact calcium binding EF-hand motifs for the structural stability of MCFD2 and point 
toward disruption of the ERGIC-53/MCFD2 interaction as the underlying mechanism for these 
mutations in causing F5F8D. 
 
Overall, this thesis work has provided new insights into the structural organisation of the 
ERGIC-53/MCFD2 transport receptor complex and highlighted the importance of calcium for 
the regulation of its function. By studying this complex the hope is that we have shed some 
light, not only on the mechanisms behind transport of FV and FVIII by ERGIC-53 and 
MCFD2, but also on general processes underlying the assisted glycoprotein transport in the 
early secretory pathway. 
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1 INTRODUCTION  
 
 
1.1 GENERAL INTRODUCTION  
 
In the evolution of the eukaryotic cell from its ancestor, the prokaryotic cell, an important step 
was the development of specialised organelles that perform dedicated functions. This 
compartmentalisation of the cell, along with the elaborate transport and delivery systems 
between the compartments, has provided the eukaryotic cell with the capacity to evolve a 
variety of cellular processes and establish multicellular organisms. Central among these 
systems is the secretory pathway, which contains organelles that have been optimised in a 
sequential pathway in order to maturate and sort proteins. This pathway was first described 
over 40 years ago by the pioneers of modern cell biology Caro and Palade (Caro & Palade 
1964). Since then the general structure underlying these processes has become more defined 
and several of the major protein components and signalling systems involved have been 
identified and their mechanisms elucidated. It is now established that proteins targeted to either 
the plasma membrane, the extracellular medium or to specific organelles within the cell are 
dependent on the correct transfer along this pathway (Mellman & Warren 2000). 
 Based on proteomic analysis it is estimated that one-third of the ~25,000 translated 
proteins in the eukaryotic genome enters the secretory pathway (Levine et al. 2005). An 
intriguing question is how all these secretory proteins are deciphered, folded, processed and 
sorted to their proper location within this machinery. Genetic and biochemical data have 
greatly increased our understanding of how the proteins within the secretory pathway function 
and interact to handle this enormous task. Nevertheless, we are still only beginning to grasp the 
extent of this complex network of interactions and processes. In order to fully understand the 
underlying molecular mechanisms governing the secretory pathway, a vital key is the 
determination of three-dimensional structures of the components in this machinery. 
 The importance of the secretory pathway has become increasingly clear and several of 
the proteins in this pathway have been linked to human diseases (De Matteis & Luini 2011). 
One of the first diseases that was genetically associated with processes in the secretory 
pathway is the combined blood coagulation factor V and VIII deficiency (F5F8D) (Nichols et 
al. 1998). More recently, it has been established that F5F8D is caused by mutations in the 
genes that codes for the ER-Golgi intermediate compartment 53 kDa protein (ERGIC-53), or 
the multiple coagulation factor deficiency protein 2 (MCFD2). Together these two proteins 
form a complex that specifically interacts and assist transport of the glycosylated blood 
coagulation proteins factor V (FV) and factor VIII (FVIII) (Zhang et al. 2003).  
In this thesis X-ray crystallography and Nuclear Magnetic Resonance (NMR) 
spectroscopy have been applied to elucidate the structure and function of the ERGIC-
53/MCFD2 transport receptor complex at a molecular level. By studying this complex the hope 
is that we have shed some light, not only on the mechanisms behind transport of FV and FVIII 
by ERGIC-53 and MCFD2, but also on general processes underlying the assisted glycoprotein 
transport in the early secretory pathway. 
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1.2 OVERVIEW OF THE EARLY SECRETORY PATHWAY 
 
After being translated on the ribosome, all proteins that travel along the secretory pathway start 
their journey in the endoplasmic reticulum (ER), and are subsequently sorted to different 
organelles, including the ER-Golgi intermediate compartment (ERGIC), the Golgi apparatus, 
endosomes and lysosomes (figure 1). Each of these organelles maintains a unique environment 
and protein composition, despite the large exchange of material throughout the pathway. The 
transmembrane and soluble proteins that traverse through these organelles are collectively 
termed secretory cargo proteins. During their journey along this pathway the secretory cargo 
proteins undergo a series of post-translational modifications that promote folding and assist in 
targeting them to the correct intra- or extra-cellular destination (Anelli & Sitia 2008).  
 
 
Figure 1. Schematic overwiev of the secretory pathway. Transport steps are indicated by arrows and 
transport vesicles: COPII in dark grey, COPI light grey and clathrin in black. Cargo destined for 
secretion leaves the ER at distinct exit sites in COPII-transport vesicles that bud off and are transported 
to the ERGIC. Cargo proteins are sorted from the ERGIC in anterograde COPII carriers that move them 
to the Golgi. After passage through the Golgi cargo proteins are delivered further in clathrin coated 
vesicles. Retrograde-directed COPI coat vesicles bud off from the ERGIC and Golgi compartments to 
recycle vesicle components and retrieve resident proteins that have escaped the ER. 
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The general principles for transport between the different organelles are similar, regardless of 
the destination. Transport vesicles bud off with the cargo proteins from one organelle and 
transport them to the subsequent organelle where they fuse with the membrane of the organelle 
and deposit the cargo proteins (Bonifacino & Glick 2004). Three classes of vesicles with 
different coat proteins, COPI, COPII and clathrin, are involved these transport events at 
different stages of the secretory pathway (Lee & Goldberg 2010). As a whole, the secretory 
pathway links organelles together to provide a framework for proteins to reach their proper 
destination correctly folded. 
The secretory pathway is not a fixed isolated system, but is highly dynamic and 
responds to the surrounding environment and different intracellular contexts. Thus, the amount 
and variety of proteins expressed and transported can rapidly and dramatically change. As a 
consequence the secretory pathway continuously remodels its architecture and modulates the 
secretion capacity in order to adapt to the quantitative and qualitative secretion demand. The 
secretory pathway also responds to changes during specific stages of development programs by 
modifying aspects of its functional organisation and protein composition (Kondylis et al. 
2009).  
Although all eukaryotic cells essentially rely on this pathway for synthesis and sorting 
of secretory proteins there are major differences between different cell types. For instance, 
specialised secretory cells, such as antibody-producing plasma cells, have increased ER size 
and enlarged Golgi volume to accommodate the production of high levels of specific proteins 
(Tagliavacca et al. 2003). In contrast, the ER and the Golgi are not as highly developed in non-
secretory cells and they produce only basal levels of proteins that reside in the secretory 
pathway to maintain their cell homeostasis. 
 
The ER 
The ER is the entry station for all secretory cargo proteins and the resident proteins of the 
secretory pathway. It consists of a membranous interconnected network of tubules, vesicles and 
cisternae, which takes up more than half of the total cellular membrane volume in most cells. 
Compared to the cytosol the ER lumen has a distinctly different milieu. For instance, the total 
concentration of Ca2+ in the ER lumen is normally in the range of 0.5-1 mM, compared to the 
nanomolar levels found in the cytosol (Prins & Michalak 2011, Pezzati et al. 1997). Moreover, 
the ER lumen has a distinct oxidising environment and chaperone systems that promote 
disulfide bond formation and protein folding (Margittai & Bánhegyi 2010). This unique ER 
environment provides the means to create an intracellular maturation playground that prepares 
secretory proteins to remain stable under challenging extracellular conditions. 
 
The ERGIC 
The ERGIC, also known as vesicular-tubular clusters or pre-Golgi intermediates, is a highly 
dynamic compartment found only in higher eukaryotic cells. As the name implies, this 
compartment is located at the interface of the ER-Golgi boundary. Although the dynamic 
nature of the ERGIC has been a matter of controversy, it is now recognised as a structurally 
distinct compartment with a unique biochemical composition (Appenzeller-Herzog & Hauri 
2006).  The ERGIC is proposed to have a different pH and a lower calcium concentration, 
compared to the ER and the Golgi. Although the exact pH of ERGIC still remains elusive, a 
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progressive acidification from the ER (pH 7.1-7.4) to the Golgi (pH 5.9-6.3) has been 
established, and the pH of the ERGIC is expected to be somewhere in between the ER and the 
Golgi (Paroutis et al. 2004).  
Measurements of calcium concentrations of the secretory pathway have revealed high 
levels of calcium in the ER (0.5-1 mM) and Golgi (0.5-1 mM), whereas calcium levels in the 
ERGIC remained below detection levels. (Pezzati et al. 1997). This drop in pH and calcium 
levels from the ER to ERGIC is believed to assist in sorting proteins and allow the ERGIC to 
function as preliminary sorting station before the Golgi. By this means, the secreted cargo 
proteins are concentrated in the ERGIC and transported towards the Golgi while the ER 
resident proteins and the recycling proteins are retrieved back to the ER.  
 
The Golgi  
The Golgi consists of a series of discrete compartments, which include the cis- and trans-Golgi, 
and the trans-Golgi network (TGN) (Glick 2000). These series of compartments play an 
important role at the crossroads of the secretory pathway by receiving proteins from the 
ERGIC, modifying them, and distributing them to various destinations. The secretory proteins 
arriving from the ERGIC enter the Golgi cis-side, travel across the series of intra-Golgi 
compartments, and leave the Golgi on the trans-face. On their way through the different 
regions of the Golgi, the secretory proteins are subjected to distinct processing and sorting 
events. Among these events, glycoproteins are modified by ordered remodelling of their N-
linked oligosaccharide side chains alongside biosynthesis and attachment of O-linked glycans. 
(Helenius & Aebi 2001, Wopereis et al. 2006). Finally before exiting the Golgi, the secretory 
cargo proteins are further sorted at the TGN and then continue their journey to their final 
destinations. 
 
 
1.2.1 Folding and quality control in the ER  
After being synthesised on the ribosome secretory proteins are targeted to the ER by a signal 
sequence at their N-terminal (Blobel 1975). After translocation into the ER, the nascent 
proteins encounter a unique folding environment provided by chaperones which prevent them 
from aggregating and foldases, which accelerate folding (Gething & Sambrook 1992). This 
folding machinery distinguishes native from non-native conformations by recognising features 
such as hydrophobic regions, glycosylation or exposed cysteins. The major portion of the ER 
chaperones belongs to three families of heat shock proteins (Hsp), Hsp40, Hsp70, and Hsp90, 
named according to their molecular weight (Cintron & Toft 2006). The Hsp70 family includes 
the central and most abundant chaperone, binding immunoglobulin protein (BiP) also named 
glucose-regulated protein of 78 kDa (GRP78) (Ellgaard & Helenius 2003).  By successive 
cycles of binding and release, driven by ATP hydrolysis, BiP assists in folding of surface-
exposed hydrophobic patches. This BiP chaperone cycle is tightly regulated and assisted by a 
set of co-chaperones that together make up a system that promotes folding and assembly by 
distinguishing and shielding hydrophobic regions (Bukau et al. 2006). 
While many of the protein folding and maturation processes in the ER are similar to 
those in the cytosol, the ER also sustains a set of covalent modifications that exclusively occur 
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in this compartment, and which for many secretory proteins are a necessity to obtain their 
native conformation. One distinctive covalent modification exclusively occurring in the ER is 
the formation of disulfide bonds, which assist in folding and stabilise the protein. This involves 
oxidation of disulfides to form bonds, as well as isomerisation of non-native disulfide bonds. 
These oxidation and isomerisation processes are assisted and regulated by ER-specific 
enzymes of the protein disulfide isomerase (PDI) and ERo1 (ER oxidoreductin 1) family 
members (Margittai & Bánhegyi 2010). Other ER-specific post-translational modifications 
include proteolytic removal of the signal sequence by the signal peptidase complex (Paetzel et 
al. 2002), GPI anchor addition by the transamidase complex, tethering proteins to membranes 
(Chatterjee & Mayor 2001), and addition of aspargine-linked glycosylation by the 
oligosaccharyltransferase (OST) complex (Mohorko et al. 2011).  
An elaborate ER quality control system works together, inseparable from the folding 
machinery, to ensure that only native conformers are transported from the ER. The existence of 
an ER quality control system was first discovered when it was found that misfolded viral 
membrane proteins were retained in the ER during their transport (Gething et al. 1986, Kreis & 
Lodish 1986). Since then it has been established that secretory proteins undergo multiple 
rounds of control for proper folding by the ER quality control system (Ellgaard & Helenius 
2003). Ultimately, correctly folded and assembled proteins are packaged into COPII-coated 
vesicles, whereas terminally misfolded proteins are re-translocated from the ER back to the 
cytosol and degraded by the ubiquitin-proteasome system, by a process known as ER-
associated degradation (ERAD) (Bernasconi & Molinari 2011). 
 
 
1.2.2 Glycoprotein folding 
The majority of the proteins that pass through the ER have a glycan attached to an asparagine 
residue that occurs in an -NXS/T- consensus sequence, where X is any amino acid except 
proline (Gavel & Von Heijne 1990). This N-linked glycosylation influences the sequence of 
folding events and acts as a sensor for the quality control machinery. In addition to this, the N-
linked glycosylation assists in targeting the secreted proteins to their correct destination in the 
secretory pathway  (Schwarz & Aebi 2011). The proteins that acquire N-linked glycans and 
pass through this system include most of the proteins present in blood, such as 
immunoglobulins, coagulation factors and several hormones.  
The N-linked glycans are added to polypeptide chains upon entry to the ER lumen. This 
addition of a branched, triglucosylated core oligosaccharide Glc3Man9GlcNAc2, to the nascent 
protein is catalysed by the OST complex (figure 2) (Mohorko et al. 2011). After transfer of the 
glycan to the polypeptide, glucosidases I and II trim the oligosaccharide moiety by sequentially 
removing the two terminal glucose residues. This generates Glc1Man9GlcNAc2, with only one 
glucose moiety attached to the folding protein (Grinna & Robbins 1980). This 
monoglucosylated protein acts as a substrate for the transmembrane lectin calnexin (CNX) and 
its soluble paralog calreticulin (CRT) (Helenius et al. 1997). These two chaperone-like lectins 
associate with the thiol-disulfide oxidoreductase ERp57, which catalyses the formation of 
intramolecular disulfide bonds in glycoproteins (Pollock et al. 2004). The folding glycoprotein 
substrates undergo multiple rounds of binding and dissociation from this chaperone system. 
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This is alternated with cycles of deglucosylation by glucosidase II, and re-glucosylation by 
UDP-glucose:glycoprotein glucosyltransferase, which recognises unfolded proteins (Helenius 
1994, Sousa & Parodi 1995). 
If the protein fails to fold correctly after prolonged periods in the CRX/CRT cycle, 
α1,2-mannosidase I removes the mannose moiety from the middle branch of the core 
oligosaccharide Man9GlcNAc2 (Tremblay 1999). This generated Man8GlcNAc2 
oligosaccharide targets the unfolded protein to the ERAD machinery, directed by the ER 
degradation-enhancing α-mannosidase I-like (EDEM) family of proteins (Kanehara et al. 
2007). In contrast, glycoproteins that obtain their correct fold can no longer be re-glucosylated 
and exit the CRX/CRT cycle, and are subsequently transported from the ER. All together, this 
elaborate system maintains glycoproteins in the ER until they are correctly folded and ensures 
the quality of the glycoproteins that exit the ER. 
 
Figure 2. Schematic overview of the Glycoprotein folding pathway. The N-linked oligosaccharide 
shown in more detail to the left with the cleavage sites of glycosidases indicated. The figure is compiled 
from articles referred to in the text. The membrane bound CNX has been omitted for clarity and only 
the folding pathway proceeding through ERp57-CRT complex is shown.  
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1.2.3 Protein exit from the ER 
Properly folded and assembled proteins that have passed the ER quality control are selectively 
sorted from ER resident proteins and concentrated into specific subdomains, known as ER exit 
sites (ERES) (Budnik & Stephens 2009). When visualised by electron microscopy these exit 
sites appear as morphologically characteristic ribosome-free regions on the ER membrane 
(Bannykh et al. 1996). The sorting of cargo proteins at ERES is tightly coupled to transport 
vesicle formation that is achieved by the components of the coat protein complex II (COPII) 
(Barlowe et al. 1994, Lee & Miller 2007). Although recent findings have shown alternative 
secretion routes, particularly under cellular stress (Giuliani et al. 2011), a majority of the 
secretory proteins rely on COPII coat transport out of the ER. The minimal machinery to drive 
COPII coat formation comprises three subunits: the small GTPase Sar1p, the Sec23p–Sec24p 
dimeric complex and the Sec13p–Sec31p heterotetrameric complex. (Lee & Miller 2007, 
Zanetti et al. 2012).  
The vesicle formation process is initiated by activation of Sar1 from the GDP-bound to 
the GTP-bound state by the membrane-bound nucleotide exchange factor Sec12p (figure 3). 
Upon binding GTP Sar1 exposes an amphipathic α-helix that is inserted into the ER membrane 
and induces curvature of the membrane, alongside recruitment of the Sec23p–Sec24p dimer. 
(Bi et al. 2002, Russell & Stagg 2010). This initial complex engages cargo proteins either by 
direct interaction with transmembrane proteins or by adaptor proteins to soluble proteins. Once 
assembled onto the ER membrane, the newly formed pre-budding cargo complex recruits the 
Sec13-Sec31 heterotetramer as an outer layer of the COPII coat. The Sec13-Sec31 outer layer 
collects pre-budding complexes, which polymerise into a cage-like structure (Russell & Stagg 
2010). This polymerisation event induces membrane scission and formation of a COPII coated 
vesicle that separates from the ER membrane. This results in a spherical membrane vesicle, 
carrying secretory cargo proteins, which is directed to and fuses with the ERGIC. These 
transport and docking events are coordinated by a highly conserved machinery involving 
numerous proteins with the key players belonging to two families: Rab GTPases, which are the 
main regulators of the events, and SNARE proteins, which drive membrane docking and fusion 
(Bröcker et al.  2010). 
 
 
1.2.4 Protein sorting 
 
Retrograde transport 
A vital aspect for maintaining the ER and ERGIC as organelles is the balance between 
anterograde (forward) and retrograde (backward) vesicular trafficking (figure 1). Retrograde 
traffic from the ERGIC and the Golgi is mediated by COPI vesicles. These vesicles assemble 
as a seven-subunit protein complex on the ERGIC and the Golgi membranes in a process that is 
activated by the GTPase ADP ribosylation factor 1. Unlike the COPII vesicles, the COPI 
vesicles recruit their coat protein coatomer in a single step. Vesicle membrane deformation and 
carrier budding is otherwise analogous to the assembly of the COPII vesicle (Hsu & Yang 
2009).  
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Alongside keeping the membrane balance within the organelles intact, the COPI vesicles also 
recycle proteins that have escaped the ER retention mechanisms back to the ER. Soluble ER 
proteins, such as chaperones and components of the quality control machinery, generally 
contain a C-terminal KDEL sequence that is recognised by the COPI associated KDEL 
receptor, which binds and retrieves the escaped proteins from the ERGIC and the Golgi (Munro 
& Pelham 1987). Membrane proteins that contain a cytosolic di-lysine KKXX-motif directly 
interact with the COPI vesicles coats and are in this way recycled to the ER (Sohn et al. 1996). 
 
Anterograde transport 
While highly abundant proteins, such as amylase, chymotrypsinogen and albumin, are 
passively exported by bulk flow (Martinez et al. 1999, Mizuno & Singer 1993), growing 
evidence supports the co-existence of selective transport processes where proteins are actively 
sorted into COPII vesicles (Malkus et al. 2002). This selective capture and sorting relies on 
specific ER export motifs within the cargo proteins. These cargo proteins can be divided into 
two classes: transmembrane proteins that are recruited by direct interaction with COPII coats, 
and soluble cargo proteins that require specific transmembrane receptors (figure 3) (Barlowe 
2003).  
A number of ER export motifs have been identified in transmembrane proteins in 
various organisms. A common feature of these ER export motifs is the location at the N- or C-
terminal exposed cytoplasmic tail. One example is a category of transmembrane cargo proteins 
that directly interacts with the Sec23p–Sec24p dimer in the initial COPII complex via an 
exposed di-acidic motif of the cytoplasmic tail, -D/EXD/E- (where X can be any amino acid). 
This motif was first revealed by mutational analysis of the cytoplasmic tail on the vesicular 
stomatitis virus glycoprotein (Nishimura & Balch 1997). Since its first identification, this di-
acidic motif has been found to be required for ER export of a number of proteins, among them 
the mammalian proteins Kir1.1 and Kir2.1 potassium channels (Ma et al. 2001), the cystic 
fibrosis transmembrane conductance regulator (Wang et al. 2004), and lysosomal acid 
phosphatase (Nishimura & Balch 1997). 
A di-hydrophobic motif (FF, YY, LL or FY) at the extreme C-terminal cytoplasmic tail 
defines another class of ER export signal that has been extensively studied in the human 
protein ERGIC-53 and the yeast homologues Emp46p and Emp47p (Kappeler et al. 1997, Sato 
& Nakano 2002). Other transmembrane cargo proteins that require this motif for efficient 
transport from the ER include the ER-vesicle protein complex Erv41/Erv46 and the p24 family 
proteins (Dancourt & Barlowe 2010). Interestingly, proteins with the di-hydrophobic export 
motifs form oligomeric complexes in order to be efficiently transported. Hence, this suggests 
that the di-hydrophobic export motif only functions within the context of a larger export signal 
connected to the oligomeric presentation of this motif.  
A recent study demonstrated that a conserved triple arginine (3R) motif, found in the G 
protein-coupled receptor (GPCR) superfamily, functions as an ER export signal for the 
multispanning transmembrane α2B-adrenergic receptor (α2B-AR). Furthermore, it was shown 
that this 3R motif, located in the third intracellular loop, facilitates ER export of α2B-AR when 
transferred to its C-terminus (Dong et al. 2012). 
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Figure 3. COPII vesicle formation and selective uptake of cargo proteins. (A) Vesicle formation is 
initiated by activation of Sar1p by nucleotide exchange factor Sec12p. Activated Sar1-GTP binds to the 
ER membrane and recruits the Sec23/24 subcomplex. The cytoplasmically exposed motif on the 
transmembrane cargo is captured by direct contact with Sec24, while transmembrane cargo receptors 
mediate the interaction of soluble cargo proteins to the Sec23/24 complex. (B) The prebudding cargo 
complex recruits the outer layer Sec13-Sec31 complex, leading to coat polymerisation and vesicle 
formation, which induces membrane scission and formation of a COPII coated vesicle loaded with 
soluble and transmembrane secretory cargo proteins. 
 
In contrast to the transmembrane cargo proteins, selective export of soluble cargo proteins 
requires specific transmembrane receptors to mediate the interaction with the COPII coats. 
These receptors recognise and bind to specific export signals within soluble cargo proteins. As 
such they not only act as transporters, but also as key components of the secretory quality 
control machinery by recognising correctly folded and assembled proteins. Even though 
concentrative sorting of soluble proteins was shown in several studies (Salama et al. 1993, 
Mizuno & Singer 1993) and transport receptors were assumed to exist already in the early 
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1990s, it is only during the past 10 years that experimental evidence supporting selective 
sorting of soluble cargo proteins has started to emerge. Still growing in numbers, several 
specific cargo receptor/cargo interactions have been identified in both yeast and mammals to 
date (table 1).  
 
 
Table 1. Protein sorting receptors in the early secretory pathway 
 
Receptor Species   Signals recognised on cargo    Oligomerisation state 
Multispanning transmembrane receptors     
 Erv29p    Yeast   I-L-V   Oligomer   
 Erv26p    Yeast   Lumenal determinant   Oligomer   
 Erv14p    Yeast   Lumenal determinant   Oligomer   
 KDEL receptor  Mammals KDEL (HDEL in yeast) Oligomer   
p24 proteins         
 Erv25p    Yeast   Unknown   Hetero-oligomer (Emp24p)  
 Emp24p    Yeast   Unknown   Hetero-oligomer (Erv25p)    
L-type lectins         
 Emp46p  Yeast   High-mannose N-glycans   Hetero-oligomer (Emp47p)   
 Emp47p  Yeast   High-mannose N-glycans   Hetero-oligomer (Emp46p)  
 ERGIC-53    Mammals   High-mannose N-glycans, β-hairpin   Hexameric 
 ERGL  Mammals Unknown Unknown 
 VIP36    Mammals   High-mannose N-glycans   Monomeric 
 VIPL    Mammals   High-mannose N-glycans   Monomeric 
 
 
1.2.5 Transport receptors  
A great deal of our current knowledge of transport receptors and their associated cargo proteins 
has been acquired by the genetic and biochemical analysis of the yeast Saccharomyces 
cerevisiae. The best characterised transport receptor in yeast, the ER-vesicle protein Erv29p, 
was first identified as a highly abundant vesicle associated integral transmembrane protein. 
Since its first discovery, Erv29p has been shown to act as cargo receptor required for the export 
of a set of soluble cargo proteins, including carboxypeptidase Y, the α-factor mating 
pheromone (gpαf) and proteinase A (Belden & Barlowe 2001, Caldwell et al. 2001). Moreover, 
from studies of the interaction of Erv29p with gpαf a specific motif of three hydrophobic 
residues (I-L-V) within a segment of the gpαf proregion was shown to be required for Erv29p-
dependent recognition. This short hydrophobic sequence motif was also found to function as an 
ER export motif when fused to the ER resident protein Karp2 (Otte & Barlowe, 2004).  
Erv14p and Erv26p are two other integral transmembrane receptors in yeast that have 
been shown to interact with cargo proteins and dynamically cycle between the ER and Golgi. 
Erv14p directly interacts with the Sec23-Sec24-Sar1 GTP pre-budding complex and mediates 
incorporation of the cargo protein Ax12p into COPII vesicles (Powers & Barlowe 2002). The 
tetra-spanning membrane protein Erv26p is required for efficient transport of the type II 
membrane proteins, pro-alkaline phosphatase and Ktr3p mannosyltransferase, by linking them 
to the COPII machinery (Bue et al. 2006, Bue & Barlowe 2009). 
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The p24 proteins comprise a family of putative cargo receptors in the 24 kDa molecular weight 
range that share a similar structural organisation, with an ER lumen oriented domain and a 
single transmembrane segment followed by an exposed cytoplasmic tail  (Strating & Martens 
2009). Members of this family form heteromeric complexes and cycle between the ER and 
Golgi in yeast. Several functions have been proposed for p24 proteins, including structural and 
regulating functions of vesicle trafficking in the secretory pathway. There are also strong 
indications that several p24 proteins are involved in protein sorting by direct interaction with 
cargo proteins, and it has been shown that two members of this family, Emp24p and Erv25p, 
form a complex that is required for efficient transport of the glycosylphosphatidylinositol-
anchored protein Gas1 (Muniz et al. 2000). 
Other proposed cargo receptors in yeast include the two type-I membrane proteins 
Emp46p and Emp47p, which form a hetero-oligomeric complex that interacts with COPII and 
COPI vesicles. Although no specific cargo proteins have been identified for Emp46p and 
Emp47p, it has been shown that gene deletion of either EMP47 or EMP46 leads to a defect in 
the secretion of a subset of glycoproteins  (Sato & Nakano 2002). Emp46p and Emp47p both 
share a conserved luminal carbohydrate recognition domain (CRD) that is homologous to 
leguminous plant lectins (L-type lectins). The recently solved crystal structures of the CRD 
from both Emp46p and Emp47p (Satoh et al. 2006) resemble the mammalian orthologue 
ERGIC-53 (Velloso et al. 2002), which has been confirmed to act as a glycoprotein receptor. In 
contrast to ERGIC-53, which relies on two bound Ca2+ ions to interact with oligosaccharide 
ligands, Emp46p binds a K+ ion, and Emp47p does not bind any metal ion. Although Emp46p 
and Emp47p have different metal binding properties compared to the canonical L-type lectins, 
in vitro studies have shown that both proteins bind glycoproteins carrying high mannose 
glycans (Satoh et al. 2006), thus strengthening the theory that Emp46p and Emp47p are 
involved in transporting glycoproteins. 
Although most identified transport receptors in yeast are conserved in mammals, it has 
been challenging to directly link the mammalian orthologues to transport of specific cargo 
proteins. The molecular-genetic methods applicable in yeast have proven more problematic in 
mammalian cells. Moreover, analysis of protein transport in yeast, which lacks the ERGIC, can 
be accommodated within a simple model in which COPII vesicles mediate transport from the 
ER to the Golgi. The addition of the ERGIC to the secretory pathway in mammals adds an 
increasing complexity to this model.  
 Thus far, with the exception of the well characterised glycoprotein receptor ERGIC-53 
and its close homologue the vesicular integral-membrane protein of 36 kDa (VIP36), there is 
no direct evidence for ER-to-Golgi transport receptor functions of yeast orthologues in higher 
eukaryotes. For example, there is no evidence for transport functions in orthologues of the well 
characterised transport receptor Erv29p from yeast. Interestingly though, the mammalian 
orthologue of Erv29p, Surf4, was recently shown to interact with ERGIC-53, and to be 
essential for maintaining the architecture of the ERGIC and the Golgi (Mitrovic et al. 2008). 
Novel functions have also been proposed for mammalian orthologues of p24 family members 
and the importance of this family of proteins in mammals has been demonstrated by deletion of 
a single family member (p23 or p24δ1) in mice, leading to embryonic lethality (Denzel et al.  
2000). In contrast, the p24 proteins seem to be dispensable in yeast, since deletion of all eight 
p24s found in yeast leads only to minor defects in cargo transport (Springer et al. 2000). 
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The best characterised transport receptor in mammals, ERGIC-53 belongs to a family of four 
type-I membrane proteins, which also includes the ERGIC-53-like protein (ERGL), VIP36 and 
the VIP36-like protein (VIPL)  (Hauri et al. 2002). In common with their yeast homologues 
Emp46p and Emp47p, these four proteins all share a conserved luminal CRD. All of these four 
mammalian lectins have been proposed to assist in glycoprotein sorting and transport in the 
early secretory pathway. However, their exact roles in these processes remain to be revealed.  
An interesting question is how the binding and release of soluble cargo proteins are 
regulated by their cognate receptors? The differences in calcium and pH levels between the 
different compartments have been proposed to influence these transport events. Thus far this 
has only been demonstrated between specific cargo proteins and ERGIC-53 (Itin et al. 1996, 
Appenzeller-Herzog et al. 2004). Furthermore, the common feature of cargo receptors to form 
oligomeric protein complexes is most likely a key event in these transport processes. It is 
possible that changes in compartment environment would influence the oligomeric state and, as 
a consequence, regulate binding affinity of the cargo to its receptor.  
 It is generally assumed that each cargo receptor accounts for efficient ER-exit of a 
limited set of soluble secretory proteins. What distinguishes these proteins from other secretory 
proteins and why have specific transport routes evolved for these proteins? The requirement for 
a combination of transport determinants, such as oligosaccharides and specific structural motifs 
within the cargo proteins, most likely limits the repertoire of possible cargo proteins for. This 
requirement for a combination of motifs ensures that only properly folded cargo proteins are 
transported further and thus functions as a complementary quality control system.  
 
1.2.6 L-type lectins in the early secretory pathway. 
The term Lectin from the Latin legere “to pick out or choose” was first introduced by William 
Boyd in 1954 in order to describe plant agglutinins ability to distinguish between erythrocytes 
of different blood types (Boyd & Shapleigh 1954). Since this first definition the knowledge of 
this family of non-enzymatic sugar binding proteins has grown considerably. Lectins have been 
found in all organisms and to serve in a wide variety of different biological functions, such as 
cell-cell recognition events and in the innate immune system. In general these proteins consist 
of multiple domains but the carbohydrate binding function can usually be ascribed to a single 
CRD (Loris 2002).  
L-type lectins are a major class of lectins that was first discovered in the seeds of 
leguminous plants. This family of lectins is primarily distinguished by the structural 
resemblance of their CRDs, which largely consist of a β-sandwich structure with a concave 
sheet and a convex sheet connected by short loops and β-bends (figure 4) (Loris 2002). These 
L-type lectins vary significantly in sugar binding preferences and several structures with 
different sugar moieties have been determined. Despite this fact, the binding site consisting of a 
negatively-charged cleft is highly conserved within the L-type lectins. Another conserved 
feature is the presence of two binding sites for metal ions in close proximity to this sugar 
binding site. The binding of these two ions, a compulsory Ca2+ ion at one site and a transition 
metal ion, usually Mn2+, at the second site, serves to orient and position the residues in the 
sugar binding site and consequently enables the recognition of specific sugars (Bouckaert et al. 
1999).  
  12
 
 
In the early 1990s, two mammalian proteins with sequence homology to L-type lectins, 
ERGIC-53 and VIP36, were discovered and linked to the secretory pathway (Schweizer et al. 
1988, Fiedler & Simons 1994). The crystal structures of the CRDs of these proteins confirmed 
their relationship and helped to define a new class of animal L-type lectins that reside in the 
secretory pathway (figure 4) (Velloso et al. 2002, Satoh et al. 2007). Since then, two related 
proteins VIPL (Neve et al. 2003 Nufer et al. 2003), and ERGL (Yerushalmi et al. 2001) have 
been discovered, and today the family of animal calcium-dependent L-type lectins comprises 
four members which all share an L-type lectin CRD. In contrast to plant L-type lectins, which 
are soluble secreted proteins, these four animal L-type lectins are all type-I membrane proteins. 
Although homologous and structurally similar, these four transmembrane lectins are 
considered to play distinctly different roles in glycoprotein sorting and transport processes in 
the secretory pathway. 
 
Figure 4. Structures of L-type lectins with bound ions shown as a dark spheres and sugars as stick 
models in black. PDB IDs in square brackets. (A) ERGIC-53 with two bound Ca2+ ions [3lcp], (B) Pea 
lectin-D-glucopyranose complex with a Mn2+ ion bound at one site and a Ca2+ ion at the second site 
[2bqp], (C) VIP36- Man-α-1,2-Man complex with a bound Ca2+ ion [2dur], (D) Emp46p with a bound 
K+ ion [2a6v].    
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The sequence and predicted domain organisation is highly similar between ERGIC-53 and 
ERGL. Both proteins share a coiled-coil domain that connects the CRD to the transmembrane 
region. This domain has been shown to be involved in the assembly of ERGIC-53 to a homo-
oligomeric complex. In VIP36 and VIPL, this domain is absent, and data have suggested that 
both proteins function as monomers (Fiedler & Simons 1996, Neve et al. 2003, Nufer et al. 
2003).  
 In all members of this family, the transmembrane segment is followed by a short 
cytosolic tail which mediates the sorting of ERGIC-53, VIP36 and VIPL within the secretory 
pathway. ERGL, on the other hand, lacks typical transports motifs in its tail and is suggested to 
be a non-cycling ER resident protein. VIPL has also been found to be confined to the ER, 
although it carries the potential ER export motif (FY). However, mutational studies have 
revealed that VIPL localisation is determined by a di-arginine-based (RKR) ER retention motif 
in its cytosolic tail (Nufer et al. 2003). 
In contrast, ERGIC-53 and VIP36 are dynamic proteins and cycle in the secretory 
pathway. The cycling properties of ERGIC-53 are determined by two motifs in its cytosolic 
tail: a di-phenylalanine motif (FF) that mediates ER export, and a di-lysine motif (KK) that 
retrieves ERGIC-53 back from the ERGIC (Hauri et al. 2000). While the ER to ERGIC cycling 
route of ERGIC-53 is well established, there is still some controversy about the cycling 
properties of VIP36. The cytoplasmic tail of VIP36 contains two non-canonical transport 
motifs, the hydrophobic (FY) ER export motif, which is also found in VIPL, and a di-basic 
(KR) retrieval motif. Although post-Golgi cycling routes have been proposed for VIP36 
(Fiedler et al. 1994), recent data suggest that VIP36 cycles between the ERGIC and the Golgi, 
and mainly localises to the Golgi (Reiterer et al. 2010).  
The sugar-binding specificities of ERGIC-53, VIP36 and VIPL were recently studied 
by frontal affinity chromatography using a pyridylaminated sugar library (Kamiya et al. 2008). 
The results revealed specific characteristic sugar binding profiles for each lectin. ERGIC-53 
showed broad specificity, but low affinity towards various high-mannose carbohydrate 
structures. In accordance with previous findings, binding was most efficient at neutral pH 7.5–
8, as found in the ER lumen. However, in contrast to what has been proposed, ERGIC-53 did 
not discriminate between monoglucosylated glycans and deglucosylated glycans. These results 
might reflect the fact that the measurements were performed using the monomeric CRD and 
that oligomerisation of ERGIC-53 is a prerequisite for specificity and affinity.  
VIP36 showed highest affinity towards the deglucosylated high-mannose A branch. 
This finding is supported by the recently determined crystal structures of VIP36-CRD in 
complex with Man-α-1,2-Man-α -1,2-Man, which corresponds to the A branch. The sugar 
binding of VIP36 was also shown to be pH-dependent, with an optimum pH of 6.5 
corresponding to the pH of the cis-Golgi. Collectively, from cycling and sugar binding 
properties a model has been proposed, where VIP36 functions in quality control of 
glycoproteins in the Golgi by recycling inadequately trimmed glycoproteins that have escaped 
the ER QC machinery (Reiterer et al. 2010).  
VIPL, the close homologue of VIP36, also shows high affinity for the deglucosylated 
high-mannose A branch. In contrast to VIP36 though, VIPL binds oligosaccharides optimally 
at pH 7.5, corresponding to the lumenal pH of the ER. From these data it has been suggested 
that the ER resident protein VIPL binds deglucosylated high-mannose glycoproteins released 
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from the CNX/CRT cycle and delivers them to ERGIC-53 for transport from the ER. In this 
manner, VIPL is predicted to protect correctly folded glycoproteins from demannosylation by 
α1,2-mannosidase I and subsequently from ERAD.  
 
 
 
1.3 THE ERGIC-53/MCFD2 TRANSPORT RECEPTOR COMPLEX 
 
 
1.3.1 ERGIC-53 
ERGIC-53, also known as LMAN1, was originally discovered as a 53 kDa protein by 
Schweizer et al. in 1988 in a monoclonal antibody screen against purified Golgi membrane 
fractions from human intestinal epithelial cells. Independently, but using a similar approach, 
Saraste and co-workers identified a 58 kDa protein in Golgi fractions from rat pancreas and 
named it p58 (Saraste et al. 1987). The p58 protein was originally believed to be a glycoprotein 
localised to the cis-Golgi, but further studies revealed p58 to be non-glycosylated and the 
sequence 89% identical to ERGIC-53 (Lahtinen et al. 1996). Since their discovery, ERGIC-53 
and the closely related rat orthologue p58, have been extensively used as model proteins to 
study mechanisms underlying protein trafficking in the early secretory pathway. ERGIC-53 has 
mainly served as a marker for the ERGIC, in which it is present at high concentrations. In these 
studies ERGIC-53 has also been found, although at lower levels, in the ER and in the cis-Golgi 
(Schweizer et al. 1988, Hauri et al. 2000). While ERGIC-53 levels are generally low in the ER, 
high localised concentrations of ERGIC-53 can be found in the ERES budding structures and 
associated with the COPII and COPI machinery (Tisdale et al. 1997, Wendeler et al. 2007). 
Collectively, these studies have established an ERGIC-53 recycling pathway from the ER to 
ERGIC accomplished through interactions of the C-terminal, di-phenylalanine (FF) ER exit 
motif and di-lysine (KK) ER retrieval motif, with the COPII and COPI vesicles. 
On the basis of initial sugar binding studies and sequence homology to L-type lectins 
ERGIC-53 was recognised as a Ca2+-dependent lectin and was proposed to be involved in ER 
export of mannose-rich glycoproteins. This theory was strengthened when it was shown that 
secretion of the lysosomal glycoproteins cathepsin C (catC) and cathepsin Z (catZ) was 
delayed in cells expressing a C-terminal KKAA-mutant variant of ERGIC-53 that is retained in 
the ER (Vollenweider et al. 1998). Subsequent studies revealed that efficient binding of catZ to 
ERGIC-53 was not only dependent on its N-linked glycan moieties, but also involved an 
exposed β-hairpin next to the glycan site (Appenzeller-Herzog et al. 2005). The interaction was 
also shown to be pH-dependent, demonstrated by the impaired binding of ERGIC-53 to catZ 
upon acidification of cells (Appenzeller-Herzog et al. 2004). Further support for ERGIC-53 to 
function as a glycoprotein receptor came from human genetics, when the cause of the bleeding 
disorder F5F8D was associated with mutations in ERGIC-53 and its transport of the heavily 
glycosylated coagulation proteins FV and FVIII (Nichols et al. 1998).  
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The list of proteins associated with processes involving ERGIC-53 has become longer since 
these first studies. In a recent study using a yellow fluorescent protein-based protein 
complementation assay, the glycosylated serine protease inhibitor α1-antitrypsin was shown to 
depend on ERGIC-53 for efficient transport from the ER (Nyfeler et al. 2008). Two other 
proteins that have been found to act as cargo for ERGIC-53 are the glycosylated membrane 
protein Nicastrin, a component of the γ-secretase complex, which has been associated with 
processes involving Alzheimer's disease (Morais et al. 2006), and Sulfatase Modifying Factor 
1, a formylglycine generating enzyme that activates sulfatases (Fraldi et al. 2008).  
In addition to ascribed cargo receptor functions, ERGIC-53 has also been associated 
with assembly and transport of secretory hexameric IgM and recently it was shown that 
ERp44, a soluble protein involved in thiol-mediated retention, interacts with ERGIC-53 and 
assists in these processes (Anelli et al. 2007). Furthermore, ERGIC-53 has been shown to 
interact with the fibroblast growth factor receptor 3 (FGFR3) and to act in pre-assembly and 
quality control mechanisms of this receptor, findings which have significant implications for 
understanding the pathogenesis of FGFR3-related disorders (Lievens et al. 2008). 
ERGIC-53 is a type-1 transmembrane, non-glycosylated protein containing a signal 
sequence that is cleaved off after mediating translocation into the ER. The mature protein 
comprises a lumenal domain, a transmembrane domain and a short cytoplasmic tail, which 
contains sorting motifs for the cycling properties between the ER and the ERGIC. The lumenal 
domain can be divided into two subdomains, an N-terminal CRD and a membrane-proximal 
stalk domain. The crystal structures of the CRD, in apo- and Ca2+-bound form, revealed a large 
carbohydrate-binding site capable of accommodating highly branched mannose glycans 
(Velloso et al. 2002, 2003). Moreover, these structures showed that binding of two Ca2+ ions 
stabilise and coordinate two loop regions in close proximity to the carbohydrate binding site, 
supporting a calcium dependent sugar binding mechanism.  
The membrane proximal stalk domain is predicted to consist of four α-helices that form 
a coiled coil structure. Two cysteines in this domain, located adjacent to the TM domain, form 
inter-molecular disulfide bonds, which in conjunction with structural determinants in the TM 
and lumenal domains, have been shown to mediate oligomerisation of ERGIC-53 (Lahtinen et 
al. 1999, Nufer et al. 2003, Neve et al. 2005). Morphological and biochemical data have shown 
that ERGIC-53 exists as homohexamers and that disulfide-linked stabilisation and proper 
oligomerisation are prerequisites for its cargo receptor function (Nufer et al. 2003, Neve et al. 
2005, Zhang et al, 2006, Zheng et al, 2010B).  
ERGIC-53 represents the best characterised cargo receptor in the early secretory 
pathway in mammalian cells and a general model for how ERGIC-53 acts a transport receptor 
for a limited set of glycoproteins has been established (figure 5), although the mechanism for 
several steps remains elusive. In this model hexameric ERGIC-53 captures correctly folded 
secretory glycoproteins in the ER and assists them through the COPII pathway to the ERGIC 
where dissociation occurs, triggered by the more acidic pH and lower calcium concentration of 
this compartment. After releasing the secretory cargo proteins, ERGIC-53 is recycled back to 
the ER in COPI vesicles for a new transport cycle, while the released glycoproteins proceed 
further through the secretory pathway. 
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Interestingly, only a limited sub-set of all glycoproteins that exit the ER have been found to 
rely on ERGIC-53 for their transport, thus implying that other determinants alongside N-linked 
glycans are required for selective cargo recognition by ERGIC-53. The surface exposed β-
hairpin loop on pro-cathepsin Z remains the only confirmed determinant in this category today 
(Appenzeller-Herzog et al. 2005). The known cargo proteins differ considerably both 
structurally and in domain organisation, and interesting challenges for future studies will be to 
reveal new structural determinants. 
 
 
Figure 5. Schematic overview of the cargo receptor and recycling of ERGIC-53. Hexameric ERGIC-53 
binds to the Man9GlcNAc2 glycan on correctly folded glycoproteins in a Ca2+ ion dependent manner. 
The cargo receptor complex is recruited to the COPII vesicle pre-budding complex by direct interaction 
between, the FF-motif in the cytosolic tail of ERGIC-53 and the Sec23/24 coat proteins. The COPII 
vesicle are then transported to and fuses with the ERGIC, where the cargo is released from ERGIC-53, 
as a consequence of the lower pH and Ca2+ ion levels of this compartment. The released cargo proteins 
continue their journey to the Golgi, while free ERGIC-53 is recruited into the COPI vesicle and recycles 
back to the ER by interaction of its cytosolic KK-signal with the COPI components. In the ER, ERGIC-
53 recruits new cargo and next transport cycle is initiated.  
 
 
 
  17
 
 
1.3.2 MCFD2, an EF-hand protein 
The first link between MCFD2 and the secretory pathway was established when it was 
identified as the second gene location of previously unexplained F5F8D causing mutations 
(Zhang et al. 2003). While the role of ERGIC-53 as a glycoprotein receptor was well 
established, less was known about the involvement of MCFD2 in transport processes in the 
secretory pathway when this project was initiated. Still to date, no other proteins except FV and 
FVIII have been found to require MCFD2 for transport, and it has been shown that knockdown 
of MCFD2 has no effect on the interaction of CatC or CatZ with ERGIC-53 (Nyfeler et al. 
2006). 
MCFD2 is a small soluble protein of 16 kDa, with an N-terminal ER translocation 
signal sequence and two C-terminal calcium-binding EF-hand motifs. Studies have shown that 
MCFD2 is localised to the ER and the ERGIC. However, in contrast to many other soluble ER-
resident proteins MCFD2 lacks the C-terminal KDEL retrieval signal that mediates recycling 
back to the ER, suggesting that localisation of MCFD2 is reliant on its interaction with 
ERGIC-53. Orthologues of MCFD2 have been found in vertebrates from mammals to fish and 
the EF-hand motifs in MCFD2 also show high sequence conservation to other EF-hand 
proteins, such as calmodulin and parvalbumin.  
 
Figure 6. Domain organisation of EF-hand proteins with bound Ca2+ ions shown as dark spheres. PDB 
IDs in square brackets. (A) Calbindin D9K containing only a single pair of EF-hands [1b1g]. (B) 
Calmodulin a four EF-hand protein with two independent domains connected by a flexible linker [1cll]. 
(C) Parvalbumin a three-EF-hand protein with a non-functional EF-hand serving to stabilise the Ca2+-
binding pair [2pvb].  (D) The S100 family member Psoriasin in absence of Ca2+ ions, a two EF-hand 
protein that exists as a homodimer, one of the monomer in colored dark grey in the figure. Structure 
solved in absence of Ca2+ ions [1psr]. 
  18
 
 
The name EF-hand was introduced by Kretsinger and derived from the initial descriptions of 
the crystal structure of parvalbumin, which was the first solved structure of protein containing 
the helix-loop-helix Ca2+-binding EF-hand motif (Kretsinger et al. 1972). Most EF-hand 
proteins contain an even number of EF-hands, which occur as interacting pairs. These pairs of 
EF-hand motifs form a structurally stable EF-hand domain through hydrophobic contacts 
among the helices flanking the Ca2+-binding loops and a network of hydrogen bonds forming a 
short antiparallel β-sheet that connects the Ca2+-binding loops (Grabarek 2006). Although 
sharing highly similar EF-hand domains, EF-hand proteins are very diverse in their domain 
architecture and in how they use these domains to function (figure 6). Consequently, EF-hand 
proteins constitute a large and diverse family of proteins that plays essential roles in a variety 
of cellular processes involving calcium regulation, such as muscle contradiction (Holmes 1996) 
and signal transduction between cellular organelles (Niki et al. 1996). 
 The canonical EF-hand motif consists of a 12-residue loop in which a Ca2+ ion is 7-fold 
coordinated in a pentagonal-bipyramidal arrangement. The consensus sequence for this motif is 
commonly described as X*Y*Z*−Y*−X**−Z, where the X, Y, and Z pairs are the Ca2+ 
coordinating ligands named according to their alignment on the approximate axes of a 
pentagonal bipyramid, and the stars represent intervening residues (figure 7). The first nine 
residues of this consensus sequence form the loop, and the final residue a Ca2+ ligand at 
position −Z, is the third residue of the following helix (Gifford et al. 2007).  
 
Figure 7. The Ca2+ co-ordination by the pentagonal bipyramid illustrated by the canonical EF-hand 1 of 
calmodulin (PDB ID 1exr). The Ca2+ ion is coordinated by side chain oxygen atoms at the X, Y, and Z 
vertices and by a backbone carbonyl at −Y. At the –X axis, a side chain oxygen coordinates the Ca2+ ion 
through a bridged water molecule and at the −Z axis, a side chain carboxylate makes a bidentate 
interaction with the Ca2+ ion. 
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The calcium binding affinities of EF-hand proteins range from Kd 10-4 to 10-9 M and have been 
shown to be highly dependent on the amino acid sequence in their EF-hand motif. Calcium 
binding to EF-hand motifs is most commonly connected to conformational changes that are 
essential for regulatory functions (Yap et al. 1999).  Accordingly, EF-hand proteins are well 
adapted to respond to changes in calcium concentrations and act in signalling events and 
protein-protein interactions.  
 
 
1.3.3 Combined deficiency of factor V and factor VIII  
Combined deficiency of factor V and factor VIII (F5F8D) is an inherited bleeding disorder, 
which was first described by Oeri et al. in 1954. The disorder is characterised by reduced 
plasma concentrations of blood coagulation factors V and VIII, with both typically in the 
region of 5–30% of normal levels. F5F8D affects males and females in equal numbers, but is 
estimated to be extremely rare in the general population (1:1,000,000) (Mannucci et al. 2004). 
Only approximately 150 patients in 90 families have been diagnosed with F5F8D, with half of 
the families originating from the Mediterranean region (Zhang et al. 2008). The high frequency 
of F5F8D in some of the communities in this region can partly be explained by a high 
incidence of consanguineous marriages.  
In general the symptoms in F5F8D patients are equivalent to those observed in patients 
with single FV or FVIII deficiencies. Affected patients present with a mild to moderate 
bleeding tendency with commonly observed mild bleeding symptoms such as easy bruising, 
gum bleeding and nosebleeds. Excessive bleeding episodes are particularly common after or 
during, dental extraction, surgery, labour or trauma. Due to these relatively mild bleeding 
symptoms and similarity in bleeding manifestation to single factor deficiencies, F5F8D may be 
significantly under-diagnosed or misdiagnosed in countries with limited genetic and 
haematology infrastructure. 
The genetics behind F5F8D was not understood until 1998 when Nichols et al. by using 
positional cloning localised disease-causing mutations to the LMAN1 gene that encodes the 
protein ERGIC-53. Although ERGIC-53 was commonly used by cell biologists and had 
already been proposed to act as a transporter for glycoproteins, this finding was unexpected. 
However, no mutations could be detected in the LMAN1 gene for approximately 30 % of the 
affected patients. The cause for the disorder in this sub-set of patients was later revealed by 
Zhang et al. in 2003, when they showed that mutations in the gene MCFD2 gave rise to the 
same clinical phenotype as mutations in LMAN1. To date at least 48 different F5F8D causing 
mutations have been located in the LMAN1 gene, all of which are null mutants except for two, 
one that disrupts the disulfide bond formation supposed to be required for proper 
oligomerisation and another that causes structural destabilisation of the CRD (Zhang et al. 
2008, Yamada  et al. 2009). In contrast to in LMAN1, the majority of the mutations in MCFD2 
are missense mutations. Among the nineteen presently reported mutations in MCFD2, ten have 
been found to result in substitutions of single of amino acid residues. 
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A direct molecular interaction between the encoded proteins was revealed by experiments in 
COS1 cells, where ERGIC-53 and MCFD2 coimmuno-precipitated (Zhang et al. 2003). 
Further experiments have confirmed this initial finding and shown that ERGIC-53 and MCFD2 
form a calcium dependent complex with 1:1 stoichiometry that specifically interacts with FV 
and FVIII and cycles between the ER and the ERGIC (Nyfeler et al. 2005, Zhang et al. 2006, 
Kawasaki et al. 2008). 
 FV and FVIII are two large plasma glycoproteins that function as essential cofactors for 
the proteolytic activation of proteases involved in the blood coagulation cascade (Mann et al. 
1988, Kane & Davie 1988). These two highly homologous proteins share a common A1-A2-B-
A3-C1-C2 domain organisation (figure 8) and undergo similar post-translational modifications, 
including signal peptide cleavage, formation of conserved disulfide bonds, and addition of 
different oligosaccharides (Camire & Bos 2009).  
 
 
 
Figure 8. Domain organisation of FV and FVIII. Both proteins consist of three A domains, each of 
~300 residues, two C domains, each of ~160 residues, and a ~900 residues heavily glycosylated B 
domain, which is cleaved off  by thrombin-mediated proteolysis in the activated protein.  
 
Although FV and FVIII are highly homologous, the amino acid sequence of their B-domains is 
not conserved. The B-domains of both FV and FVIII, however, share the common feature of 
being extensively glycosylated, containing 25 and 18 consensus sites for N-linked 
glycosylation, respectively. It has been shown that efficient transport of FVIII from the ER 
requires an intact glycosylated B-domain (Miao  et al. 2004), implying that the interaction 
between the sugars on the heavily glycosylated B-domain and the CRD of ERGIC-53 are 
essential for efficient transport of FV and FVIII. A sugar dependent interaction has also been 
confirmed by mutations in the Ca2+-ion and sugar binding sites of the CRD disrupting the FV 
and FVIII interaction (Zheng et al. 2010A).  
The role of MCFD2 in the transport of FV and FVIII is more puzzling. The findings 
that unglycosylated FVIII can still interact with MCFD2 (Zhang et al. 2005), and that MCFD2 
mutants, which fail to coimmuno-precipitate with ERGIC-53 retain their ability to interact with 
FVIII (Zheng et al. 2010A), suggests that MCFD2 interacts directly with FV and FVIII via a 
protein-protein interaction. A common structural motif for this interaction most likely does not 
involve the B-domain of FV and FVIII, but can be found in one of the other more conserved 
domains. Although the cargo receptor function of the ERGIC-53/MCFD2 complex today is 
well established, key questions still remain regarding the different roles of the proteins and 
how they recognise and interact with FV and FVIII. 
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2 AIM OF THE THESIS 
 
The overall aim of this thesis project was to gain insights into how selectively mediated 
glycoprotein traffic in the secretory pathway is organised and controlled. In order to elucidate 
these processes, the ERGIC-53/MCFD2 glycoprotein transport receptor complex has been 
structurally characterised by X-ray crystallography and NMR spectroscopy. 
 
The specific aims of the thesis project were: 
1. To determine the three-dimensional structure of human MCFD2 and give insights into 
the observed Ca2+ ion dependent MCFD2 binding to ERGIC-53. 
2. To determine the structural organisation of the ERGIC-53/MCFD2 glycoprotein 
transport receptor complex at a molecular level. 
3. To facilitate understanding of the function and the mechanism by which mutations in 
MCFD2 cause F5F8D. 
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3 RESULTS AND DISCUSSION  
 
 
3.1 NMR studies and biophysical characterisation of MCFD2 (Paper I) 
 
Since the first link between MCFD2 and the secretory pathway was established (Zhang et al. 
2003) it has attracted the interest of our group. Although clearly shown to be required for 
efficient transport of FV and FVIII, the precise role of MCFD2 in these processes was an 
enigma. It had been suggested that Ca2+ binding of MCFD2 was a prerequisite for formation of 
a functional ERGIC-53/MCFD2 transporter complex, but no structural evidence was available 
to prove this theory when the work described in paper I of this thesis was initiated. In order to 
facilitate understanding of the function of MCFD2 we initially aimed to determine the structure 
of human MCFD2 by X-ray crystallography. However, after extensive crystallisation efforts 
which did not produce diffracting crystals, NMR studies on MCFD2 was initiated in 
collaboration with Professor Torleif Härd at the Swedish NMR Centre at the University of 
Gothenburg. 
 
 
3.1.1 NMR spectroscopy and structure determination 
A construct encoding the complete mature sequence of human MCFD2, excluding the signal 
sequence, was used to produce native and isotope-labelled (15N and 13C/15N) protein in E. coli 
for the NMR experiments. Unexpectedly, all spectra collected in traditional calcium free NMR 
buffers showed the characteristics of an unfolded protein, with no evidence of secondary 
structure or a hydrophobic core. This is for instance apparent in the 15N-HSQC spectrum of 
MCFD2, which shows poorly resolved amide resonances in the random coil region with 1H 
chemical shifts clustered near 8.0 ppm (figure 9a). However, upon addition of calcium ions the 
spectrum of MCFD2 shows a marked difference with a new set of well-dispersed peaks 
appearing, indicative of both secondary and tertiary structure (figure 9b).  
 
Figure 9. Changes in the 15N-HSQC NMR spectrum of MCFD2 on addition of calcium. (A) Spectrum 
recorded in the absence of calcium and (B) after addition of 10 mM CaCl2, with the assignments 
indicated for all backbone NH resonances in the ordered domain. 
  23
 
 
Due to the observed calcium-dependent folding of MCFD2, all NMR spectra used in the 
structure calculations were recorded in the presence of calcium ions. Even in the presence of 
calcium ions, MCFD2 is not completely folded and some disorder remains; this can be 
observed in the 15N-HSQC spectrum as intense resonances clustered in or close to the random-
coil region (figure 9b). 
Several multidimensional heteronuclear NMR spectra were recorded to obtain the 
resonance assignments of 1H, 13C and 15N nuclei for the structure calculation. Despite the 
observed disorder in the spectra, nearly complete backbone assignments were achieved with 
the exception of a limited set of residues in the disordered regions. In the ordered region of the 
structure almost complete side-chain resonance assignment was accomplished, but due to 
poorly resolved resonances several side-chains could not be assigned in the disordered regions.  
 
Figure 10. Structural order and disorder in MCFD2 in the calcium-bound state. (A) NOE restraint 
statistics—the number of NOEs assigned for each residue. Inter-residue NOEs are shown in dark grey, 
sequential NOEs in white, short nonsequential NOEs in black and long-range NOEs in light grey. (B) 
Deviation from random-coil chemical shifts (secondary 13Cα chemical shift values; δΔ 13Cα). 
Unassigned Cα resonances are denoted by *. 
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A total of 2142 NOE-derived distance restraints were assigned and from the distribution of 
these the disordered regions could be localised to the N-terminal residues 27–66 and residues 
102–112 in a flexible loop region, both of which contain very few medium- or long-range NOE 
restraints (figure 10a). Providing further support for the NOE data analysis, the deviations from 
random-coil Cα chemical shift values are small in these regions, in contrast to those in the EF-
hand motifs (figure 10b). Based on the assignments secondary structure elements were defined 
by the chemical shift indices (CSI) of Hα, Cα, Cβ and C´ using the program TALOS and 
confirmed with HN-HN and HN-Hα NOE connectivities. At the final stage the solution 
structure of MCFD2 was calculated by automated iterative NOE assignment and structure 
calculations by simulated annealing (SA).  
 
 
3.1.2 Description of the overall structure 
The final representative ensemble of structures of the complete protein and the ordered domain 
are shown in figure 11. The first ordered region with secondary structure in MCFD2 begins at 
residue 69 in helix 1. The structured part of MCFD2 contains four α-helices and two short anti-
parallel β-strands. The overall fold is similar to other EF-hand proteins, with the two EF-hands 
packed against each other to form a single structural domain.  
 
 
 
Figure 11. The ensemble of the 20 lowest energy SA structures of MCFD2. (A) the complete structure 
and (B) only the ordered region, residues 67–146 (PDB ID 2vrg). 
 
Overall MCFD2 shows a high degree of structural similarity to other EF-hand proteins, with 
the C-terminal domain of calmodulin being most similar. However, despite this similarity there 
are differences with the most evident being the significantly longer loop connecting the two 
EF-hand motifs, and the second helix, which in MCFD2 is slightly bent and packed more 
tightly into the structure than in structural homologues (figure 12). This second helix is held in 
this bent conformation by interactions with residues within the C-terminal and the long loop 
region between the two EF hands. Interestingly, the residues at the C-terminal end of this 
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second helix and the following loop fragment show backbone amide resonance broadening, 
indicative of conformational interconversions on the microsecond to millisecond time scales. 
This suggests that the second helix and the proceeding loop can adopt two or more 
conformations. This finding was later confirmed in the crystal structure of MCFD2 in complex 
with ERGIC-53, which revealed significant conformational changes in this region upon 
complex formation.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Superposition of the MCFD2 
structure determined by NMR (dark grey) 
and a representative EF-hand domain, the 
structure of soybean calmodulin (light grey) 
(PDB2roa) 
 
Another interesting region of MCFD2 is the disordered N-terminus, which is highly conserved 
within MCFD2 orthologues, but shows very low sequence identity to other proteins. It is 
unlikely that this conserved region plays no role in the function of MCFD2. Although 
speculative, a possible scenario is that this region could adopt a more ordered conformation 
upon binding the cargo proteins FV or FVIII and form part of an interaction surface. 
 
 
3.1.3 Calcium induced folding of MCFD2 
Circular Dichroism (CD) spectroscopy performed in the presence and absence of calcium ions 
confirmed the apparent calcium-dependent folding of MCFD2 seen in the NMR spectra. The 
far-UV CD spectrum of MCFD2 in the absence of calcium is typical of an unfolded disordered 
protein, as shown by the strong contribution from negative ellipticity around 200 nm (figure 
13a). Although predominantly disordered, the weak negative ellipticity appearing as a shoulder 
around 220 nm indicates the presence of some residual secondary structure elements. The CD 
spectrum in the presence of calcium ions shows a marked difference, with a dominating 
contribution from α-helical secondary structure with minima at 207 and 222 nm and a change 
of sign from negative to positive at 197 nm. Collectively, the NMR and CD data suggest that in 
the absence of calcium MCFD2 has some transient helical structure but no hydrophobic core. 
Upon addition of calcium, the helical state becomes fully populated and folding of the protein 
occurs, with formation of the hydrophobic core. 
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The calcium-dependent folding was further studied by monitoring the CD signal at 222 nm as a 
function of calcium concentration (figure 13b). The negative ellipticity at this wavelength, 
which is primarily due to the contribution from α-helical secondary structure, increases sharply 
between 0 to 0.5 mM calcium and continues to increase up to a concentration of at least 1 mM. 
Interestingly, the calcium dependent folding profile of MCFD2 observed in this study is 
strikingly similar to the calcium dependence of the MCFD2/ERGIC-53 interaction shown in 
vitro by Kawasaki et al. Taken together, these data strongly imply that calcium binding and 
consequent folding of MCFD2 are a requirement for the formation of the MCFD2/ERGIC-53 
complex to occur.  
 
 
Figure 13. CD measurements of MCFD2. (A) Far-UV CD spectra of MCFD2 recorded in the absence 
of calcium (dotted line) and in the presence of 10 mM calcium (continuous line). (B) Calcium titration 
of the change in ellipticity at 222 nm.  
 
In summary, we determined the first structure of MCFD2 and provided a detailed description 
of the protein. The results show MCFD2 to be disordered in the absence of calcium ions and to 
adopt a structure consisting of two EF-hand motifs on binding calcium ions. However, even in 
the presence of calcium ions the N-terminus remains disordered and there is large 
conformational flexibility in the extended loop connecting the two EF-hand motifs. Overall, 
these results gave a first insight into Ca2+ as an allosteric regulator of MCFD2 binding to 
ERGIC-53, by revealing the Ca2+ dependent mechanism behind the interaction. 
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3.2 The ERGIC-53/MCFD2 transport receptor complex (Paper II) 
 
 
3.2.1 Interaction analysis and construct design 
Although the cargo receptor function of the ERGIC-53/MCFD2 complex in the transport of FV 
and FVIII was already well established, the structural organisation of this complex remained 
elusive when the work described in paper II of this thesis was initiated. From cross-linking 
experiments in COS-1 cells, MCFD2 and ERGIC-53 were known to form a 1:1 Ca2+-dependent 
complex (Zhang et al. 2006). We quantitatively measured this interaction in vitro using surface 
plasmon resonance (SPR) and isothermal titration calorimetry (ITC). The results confirmed 
that MCFD2 specifically binds to ERGIC-53 in the presence of calcium, with a Kd in the lower 
nM range, and that the interaction is disrupted in the absence of calcium. SPR data also 
demonstrated that F5F8D causing mutant variants of MCFD2 have affinities for ERGIC-53 
that are reduced by 2–3 orders of magnitude (table 2). These data are consistent with the 
findings of Kawasaki et al. that were published at the same time as our study. By performing 
SPR assays on constructs of different length of ERGIC-53 and MCFD2 we mapped the 
interaction between the proteins to the CRD of ERGIC-53 (ERGIC-53-CRD, residues 58–146) 
and the two EF-hand motifs at the C-terminus of MCFD2 (MCFD2-ΔN, residues 32–277). 
These two truncated protein variants showed an equally strong interaction, with a Kd value of 
35 nM, as the longer constructs in the SPR measurements (table 2).  
 
Table 2. SPR analysis of the interaction between ERGIC-53 and MCFD2.  
 
A                                                      B 
MCFD2 variants Kd (nM)   ERGIC-53 variants Kd (nM) 
Wild-type 30   CRD 10 
MCFD2-ΔN 35   CRD-2H 35 
D122V 5900       
D129E 7700       
I136T 6000       
ΔSLQ 3300       
 
Measurements were performed in the presence of 5 mM CaCl2 on a Biacore 3000 instrument. (A) Kd 
values from analysis of MCFD2 variants, including wild-type MCFD2, MCFD2-ΔN and F5F8D 
causing mutant variants, injected over a sensor chip with immobilised ERGIC-53-CRD. (B) Kd values 
from analysis of immobilised wild-type MCFD2 on a sensor chip and injected variants of ERGIC-53, 
including the isolated CRD and the CRD and two proximal helices of the stalk domain.   
 
On the basis of the SPR analysis, a protocol for E. coli expression and purification of the 
complex of MCFD2-ΔN and the ERGIC-53-CRD was established. The proteins were purified 
separately by nickel- and glutathione affinity chromatography, subsequently mixed and applied 
to a size exclusion chromatography (SEC) column. Analytical SEC, cross-linking experiments 
and mass spectrometry confirmed a homogeneous 1:1 complex between MCFD2-ΔN and 
ERGIC-53-CRD. Crystallisation trials of this complex initially yielded clusters of small plate 
like hexagonal crystals in a single condition. Further optimisation of this condition resulted in 
single crystals that were used for data collection.    
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3.2.2 Crystallisation and structure determination 
The complex of MCFD2-ΔN and ERGIC-53-CRD crystallised in space group P61 with two 
molecules in the asymmetric unit. The thin plate-like morphology of the crystals, in 
combination with merohedral twinning and a long cell axis of 396.9 Å, complicated data 
collection and processing. Despite these complications, the structure of the complex could be 
solved by molecular replacement and refined to 2.45 Å resolution by using the CRD of rat 
ERGIC-53 as a search model (table 3). The electron density map is essentially complete from 
residue 41–274 in the CRD and, with the exception of a few solvent exposed side chains, all 
residues are well-defined. MCFD2 is less well ordered, and density is missing for the N- and 
C- terminal residues, as well as for the loop connecting the two EF-hand motifs, thus only 
residues 66–98 and 110–144 of MCFD2 could be modelled.  
 
Table 3. Data collection and refinement. 
 
Data collection      Refinement and model building statistics 
Space group P61    Reflections in work set  25039 (1672) 
Unit cell  a = 56.6 Å, c = 396.9 Å    Reflections in test set  1426 (87) 
Resolution (Å)  2.45    Rfactor  19.6 (26.1) 
Unique reflections  26465    Rfree  24.7 (40.5) 
Redundancy  11.8 (7.3)    Number of protein atoms  4695 
Rsym (%)  12 (30)    Average B-factors (Å2)   
I/σ 17.6 (5.8)    ERGIC-53-CRD 23.6 
Completeness (%)  98.9 (85.6)    MCFD2 -ΔN 27.8 
‹B› Wilson plot (Å2)  43.0    Bond length R.M.S.D. (Å)  0.016 
       Bond angle R.M.S.D. (°)  1.47 
       Ramachandran plot   
         Percentage in preferred regions 93.9 
         Percentage in disallowed regions  0.8 
         Twin fraction   
         .h, k, l  0.732 
         .-h - k, k, - l 0 0.268 
 
Numbers in parenthesis refer to highest resolution shell (2.51–2.45 Å). 
 
In the crystal, two different packing interactions occur between the ERGIC-53-CRD and 
MCFD2-ΔN molecules: first a major interaction burying a surface area of 850 Å2, and secondly 
an interaction, likely to be crystal contact, which buries a smaller surface area of 590 Å2 and 
includes only two hydrogen bonds and one salt bridge. A structure of the ERGIC-53-
CRD/MCFD2 complex determined from un-twinned crystals in another space group, which 
was published at the same time as ours (PDB ID 3a4u) (Nishio et al. 2009), confirmed the first 
of these to be the correct biologically relevant interaction. Superposition shows the two 
complex structures to be essentially the same, with the major interaction surface common to 
both. Recent in vivo experiments further confirmed the first interaction surface to be correct, by 
demonstrating that mutation of residues in this interaction surface abolishes the binding of 
MCFD2 to ERGIC-53 (Zheng et al. 2010A). 
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3.2.3 Overall structure of the complex 
The CRD of ERGIC-53 comprises a globular β-sandwich fold consisting of a concave β-sheet 
and a convex β-sheet (figure 14). On the concave face of the CRD two calcium ions are bound 
and form the presumed carbohydrate ligand binding site. Overall the CRD in complex with 
MCFD2 is highly similar to the crystal structure of the uncomplexed ERGIC-53-CRD from rat 
and superposition of the two structures gives an R.M.S.D. of 0.32 Å for 227 C-atoms. The 
only minor structural changes that occur upon complex formation are at the interface with 
MCFD2, found on the side opposite to the carbohydrate recognition site. The location of the 
interface, and fact that only localised conformational changes occur in this region suggest that 
the cargo carbohydrate binding of ERGIC-53 is neither directly nor allosterically influenced by 
the interaction with MCFD2.  
 
Figure 14. Structure of the complex. MCFD2 (grey) and the CRD (dark grey) (PDB ID 3lcp). The 
presumed carbohydrate binding site on the CRD is indicated with an arrow.  
 
In contrast to the CRD, MCFD2 undergoes significant conformational changes upon complex 
formation. A comparison between MCFD2 in the complex and the lowest energy NMR 
structure of free MCFD2 gives an R.M.S.D. of 2.3 Å for 59 C-atoms. Unexpectedly, and in 
contrast to most EF-hand proteins which commonly interact with a hydrophobic cleft opposite 
to the Ca2+ binding EF-hand motif, MCFD2 binding to ERGIC-53 involves the two Ca2+-
binding loops. Overall, the organisation of the ERGIC-53-CRD/MCFD2-ΔN complex is 
unexpected and raises new questions on how the complex interacts with its cargo proteins FV 
and FVIII.  
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The previous findings that mutations in the sugar binding site of the CRD disrupt the binding 
to FV and FVIII, and that unglycosylated FVIII still can interact with MCFD2, suggest the 
existence of two separable interactions between the ERGIC-53/MCFD2 complex and the cargo 
proteins FV and FVIII; a glycosylation dependent interaction mediated by the ERGIC-53-
CRD, and protein-protein interaction mediated by MCFD2. Interestingly, binding of the cargo 
protein simultaneously to the carbohydrate site on the CRD and to MCFD2 would require the 
cargo to reach over a distance of more than 45 Å on the CRD (figure 14). Considering that 
ERGIC-53 assembles into hexamers during cargo transport in vivo, a perhaps more likely 
scenario is that while the sugar moieties on a cargo protein binds to the CRD, the protein 
component of the cargo interacts with MCFD2 bound to a neighbouring CRD. Analysis of the 
packing interactions in the crystal does not reveal any assemblies corresponding to an 
oligomeric receptor complex. Future studies including the stalk domain of ERGIC-53, which 
have shown to mediate the oligomerisation in vivo, will be of high interest in order to reveal 
exactly how the ERGIC-53/MCFD2 complex interacts with FV and FVIII. 
 
 
3.2.4 The interface between ERGIC-53 and MCFD2 
The interface between the ERGIC-53-CRD and MCFD2 buries a surface area of 830 Å2, which 
is surprisingly small considering that it mediates an interaction with a Kd value of ~35 nM. The 
interaction involves a combination of hydrophobic and charge interactions, including six 
hydrogen bonds, three ionic interactions and a few water-mediated hydrogen bonds (figure 15). 
The interaction area on the CRD is limited to one region and mainly involves residues from the 
first β1 strand and the following loop (H43-F66). In contrast, 17 % of the surface area of the 
ordered part of MCFD2 is buried upon complex formation with residues from both of the Ca2+-
binding loops and helix 3 mediating interactions to the CRD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. The interface between MCFD2 (grey) and the 
CRD (dark grey). Hydrogen bonds are shown as dashed 
lines and interacting residues are shown as sticks and 
labelled.  
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Interestingly, the interaction surface involves a number of previously reported F5F8D-causing 
missense mutations, and several of these contribute directly to the interaction (D89A, D89N, 
D122V, D129A and Y135N). For instance D89, positioned in the first Ca2+ binding loop, forms 
a salt bridge to K53 in the CRD upon complex formation. D122, positioned in the third helix 
which is tilted towards the CRD in the complex, forms a hydrogen bond with the side chain of 
Y48 on the CRD. From the second Ca2+ binding loop, D129 forms a water mediated bond to 
the side chain of R45 and Y135 packs against residue F46 in the CRD. Additional residues in 
MCFD2 which contribute to the interaction include N132, which forms a hydrogen bond with 
the carbonyl of P274, and E114, at the end of the third helix, that forms a salt bridge with K96 
in the CRD. 
 
 
3.2.5 Structural changes in MCFD2 upon complex formation 
The major conformational changes which occur in MCFD2 upon complex formation are 
located outside of the Ca2+ binding EF-hand motif (figure 16). In comparison to the NMR 
structure of free MCFD2, the third helix is tilted towards the CRD by approximately 20° in the 
complex. Furthermore, the second helix, which is slightly bent in the NMR structure of 
MCFD2, is straightened out in the complex. The loop following this helix, which was shown to 
be highly flexible in the NMR structure, is not visible in the electron density, indicating that 
this region remains flexible in the complex. Electron density is also missing for the last three 
C-terminal residues of MCFD2 in the complex. These residues are part of the core structure 
and interact with bent second helix in the NMR structure of MCFD2, thus the missing electron 
density implies that these intramolecular interactions are lost upon complex formation.  
 
 
 
Figure 16. Superposition of the MCFD2 structure determined by NMR (light grey) and MCFD2 in the 
complex (dark grey).  
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Collectively, these conformational changes result in a more open conformation, which exposes 
the hydrophobic core of MCFD2 on the opposite side of the Ca2+-binding EF-hand motif 
(figure 16). A common feature of EF-hand proteins is that Ca2+ binding induces the exposure 
of the hydrophobic core and provides the interaction site for target molecules (Yap et al. 1999). 
It is plausible that the hydrophobic surface area exposed on MCFD2 upon complex formation 
with ERGIC-53 could act in an analogous fashion, and provide an interaction surface for the 
cargo proteins FV and FVIII. Interestingly, several residues in the Ca2+ binding EF-hand motif 
interact with residues in the CRD in the complex. One could imagine a mechanism where 
calcium levels regulate the interaction between these residues, and thus the exposure and 
closure of the hydrophobic core. However, the exact mechanism for such a regulatory process 
involving the hydrophobic interaction surface on MCFD2 in the transport of FV and FVIII is 
yet to be proven. 
 
In summary, the structure of the ERGIC-53-CRD/MCFD2-ΔN complex provided the first 
molecular view of the organisation of a cargo receptor complex in the secretory pathway.   
Overall the organisation of the complex was unexpected and the structure revealed that 
MCFD2 undergoes significant conformational changes upon complex formation, while only 
localised changes occur in ERGIC-53.  
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3.3 Characterisation of F5F8D causing mutations in MCFD2 (Papers 
I, II and III) 
 
To date, nineteen mutations in MCFD2 have been reported in patients with F5F8D. Among 
these, ten are deletion or splicing mutations predicted to result in truncated protein products, 
including one which creates a stop codon at position 122, effectively deleting the last three 
amino acids of the protein (ΔSLQ) (Nyfeler  et al. 2008). The additional nine are missense 
mutations, all of which alter amino acid residues located within the EF-hand domain of 
MCFD2. All of these missense mutations have been shown to result in reduction of plasma 
levels of FV and FVIII with both typically in the range of 5–15 % of normal levels (table 4). 
Five of these mutations have been expressed in COS-1 cells and were found to severely impede 
the binding of MCFD2 to ERGIC-53 (D81Y, D89A, D122V, D129E and I136T) (Zhang et al. 
2003, 2008). Furthermore, in these studies the expressed MCFD2 mutant variants localised to 
the ER, whereas wild-type MCFD2 co-localised with ERGIC-53 in the ERGIC, thus 
confirming both the impaired interaction between the proteins, and that MCFD2 is reliant on 
ERGIC-53 for its proper intracellular localisation (Zhang et al., 2003, 2008). In vitro surface 
plasmon resonance analysis of recombinant proteins has demonstrated the MCFD2 mutants, 
D122V, D129E and I136T, to have affinities for the CRD of ERGIC-53 that are reduced by .2–
3 orders of magnitude (Kawasaki et al. 2008, own unpublished data). Although extensively 
studied, the molecular mechanism by which mutations in MCFD2 cause F5F8D was poorly 
understood when the work described in papers I, II and III of this thesis was initiated. 
 
 
Table 4. F5F8D patients with reported missense mutations in MCFD2, their 
geographic origin, sex and FV and FVIII levels in % compared to normal values.  
 
Origin Sex FV FVIII Mutation Reference 
Tunisia M 8 5 p.D81H  (Abdallah 2010) 
Tunisia M 9 7 p.D81H  ײ 
Saudi Arabia F 8 6 p.D81Y (Zhang 2008) 
Saudi Arabia F 13 12 p.D81Y ײ 
Tunisia F 10 19 p.D89N (Elmahmoudi 2011) 
Greece F 7 5 p.D89A (Zhang 2006) 
India F 13 14 p.D122V (Jayandharan 2007) 
Venezuela M 9 7 p.D129E (Zhang 2003) 
Poland F 11 17 p.Y135N (Ivaskevicius 2008) 
Poland M 13 38 p.Y135N ײ 
Kosovo F 4,5 1,5 p.I136T (Zhang 2003) 
Venezuela M 9,4 9 p.I136T ײ 
Venezuela F 4,3 7,4 p.I136T ײ 
Venezuela F 6,2 8,2 p.I136T ײ 
S. America F 11,5 12 p. ΔSLQ (Nyfeler 2008) 
 
*included in table the nonsense mutation ΔSLQ characterised in this study  
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3.3.1 NMR- and CD-spectroscopy analysis 
NMR and CD spectroscopy analysis of two disease causing mutations, D129E and I136T, 
revealed that both these mutations cause structural destabilisation and prevent folding of 
MCFD2 (paper I). The 15N-HSQC spectra of these mutant variants demonstrated profound 
changes compared to the wild-type spectrum of MCFD2. Even though recorded in the presence 
of calcium, the spectra of each mutant show poorly resolved resonances and resemble the 
spectrum of the unfolded apo form of MCFD2 (figure 17). CD spectroscopy analysis further 
confirmed the lower degree of folding, with each mutant resulting in spectrum profiles 
reminiscent of the calcium-free unfolded form of MCFD2 (figure 17d).  
 
Figure 17. 15N-HSQC NMR spectra recorded in the presence of calcium of the mutant variants. (A) 
wild-type MCFD2, (B) D129E and (C) I136T. (D) The CD spectra of the mutants D129E (grey 
continuous line) and I136T (black continuous line) recorded in the presence of calcium together with 
wild-type MCFD2 recorded in the presence (broken black line) and absence of calcium (broken grey 
line).  
 
The results of this study provided the foundation for our subsequent analysis of F5F8D causing 
mutations reported in MCFD2 (Paper II and III). In these studies the CD-signal at 222 nm, 
which is primarily due to contribution from α-helical secondary structure, was monitored as a 
function of temperature in order to characterise mutants with CD spectra resembling that of the 
Ca2+-bound form of wild-type MCFD2. The obtained thermal unfolding profiles demonstrated 
a decrease in secondary structure stability, and yielded lower melting temperatures (Tm) 
compared to wild-type MCFD2, for all except one of these mutants (figure 18). From this data, 
and our previous structural characterisation of ERGIC-53 and MCFD2, the consequences of all 
known F5F8D causing missense mutations found in MCFD2 could be explained at a molecular 
level. 
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Figure 18. (A) The interface between MCFD2 (grey) and the CRD (blue) showing the positions of the F5F8D-
causing mutations on MCFD2. The positions of the mutations analysed by CD in paper 2 shown as sticks and 
coloured in orange (D81Y), pink (D89A), green (D122V), cyan (Y135N) and yellow (DSLQ). Mutations 
analysed by NMR in paper 1 shown in grey (D129E and I136T). Close up view of the first (B) and second (C) 
Ca2+-binding motif with positions of the mutated residues shown as sticks in grey and with interacting residues 
in ERGIC-53 in light blue. (D) Far-UV CD spectra of wild-type MCFD2 and F5F8D mutant variants recorded 
in presence of calcium. Mutant data are shown with the same colour coding as in (A) and with folded wild 
type in grey. (E) Thermal unfolding experiments performed monitoring the CD signal at 222 nm, colour 
coding as in the Far-UV CD spectra. 
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Table 5. Tm values of MCFD2 variants. 
 
MCFD2 Tm (ºC) 
Wild-type 59   (+/-0.2) 
D81H n.d 
D81Y n.d 
D89A 43   (+/-0.2) 
D89N 45   (+/-0.1) 
D129E n.d 
I136T n.d 
Y135N 34   (+/-0.3) 
V100D 44   (+/-0.1) 
D122V 58   (+/-0.2) 
dSLQ 34   (+/-0.6) 
 
 
3.3.2 Mutations in the first Ca2+-binding motif - D81Y, D81H, D89A and D89N  
The CD spectra of the mutants D81Y and D81H both resemble the disordered apo state of 
wild-type MCFD2, indicating that these two mutants have lost the ability to bind Ca2+-ions and 
are essentially unfolded (figure 18d). D81 is the first residue of the EF-loop consensus 
sequence and binds Ca2+ through a side-chain oxygen atom. The conservation of aspartate at 
this position is 100% and this residue forms several intra-loop hydrogen bonds, contributing to 
the precise arrangement of the loop (Gifford et al. 2007) (figure 18b). In light of this, it is not 
unexpected that substitution of this amino acid prevents correct formation of the EF hand motif 
and by this means disrupts the core structure of the protein.  
In contrast, the CD spectra of the mutants D89A and D89N are highly similar to the 
spectrum of the calcium bound form of wild-type MCFD2 (figure 18d). However, thermal 
unfolding profiles demonstrate a decrease in structural stability and yield melting temperatures 
~15 °C lower than that of wild-type MCFD2 for both mutants (figure 18e, table 5). The residue 
D89 occupies the ninth position in the EF-hand loop and contributes to the arrangement of the 
loop by forming a hydrogen bond to a water ligand of the Ca2+ ion to complete the pentagonal 
bipyramid (figure 18b). Moreover, the carboxyl group of the side chain of D89 caps the N-
terminus of the helix following the EF-hand loop. The mutations D89A and D89N result in 
loss of these two interactions and give rise to structural destabilisation demonstrated by their 
lower Tm values. In addition, upon complex formation D89 forms a salt bridge with K53 in 
ERGIC-53, and substitution of this residue most likely disrupts this interaction and results in 
attenuation of binding affinity. 
 
 
3.3.3 Mutations in the second Ca2+-binding motif - D129E, Y135N, I136T  
NMR and CD spectroscopy demonstrate that the mutations D129E and I136T abolish 
secondary and tertiary structure in MCFD2 (figure 17). D129 occupies the first highly 
conserved position of the EF-loop and, as for D81 in the first EF-hand, substitution of this 
amino acid prevents binding of Ca2+ ions and thereby disrupts the core structure of the protein 
(figure 18c). 
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I136 occupies the eighth position of the EF-hand loop and does not directly bind calcium, but 
is situated between two Ca2+ ligands. The exact identity of the residue at this position is not 
conserved, but it is always hydrophobic (Gifford et al. 2007). In wild-type MCFD2 the side 
chain of I136 faces away from the Ca2+ ion binding site, and is instead packed with other 
hydrophobic side chains in the small hydrophobic core of MCFD2. Substitution of this 
isoleucine to a polar threonine most likely disturbs packing of this small hydrophobic core, and 
thereby results in a disordered protein. 
The observed decrease in secondary structure stability for the Y135N mutation, 
demonstrated by the significantly lower Tm value of 34 °C compared to 59° C for wild-type 
MCFD2, is presumably due to the cooperative disturbance of two interactions. This tyrosine 
occupies the seventh position of the EF-hand loop and binds Ca2+ ion through its main-chain 
oxygen (figure 18c). In addition, the aromatic ring of this residue is involved in hydrophobic 
interactions with L87 in the first EF-hand. This hydrophobic interaction is most likely 
disrupted by the Y135N substitution, and as a consequence the specific conformation of Y135 
in the Ca2+-binding loop is distorted, resulting in breakage of the bond between the main-chain 
oxygen and the Ca2+ ion. Thus, the loss of these interactions most likely leads to destabilisation 
of the protein. Furthermore, in the complex of the ERGIC-53-CRD and MCFD2, Y135 packs 
against F46 in ERGIC-53 through interactions between their aromatic rings and the Y135N 
substitution therefore weakens this interaction. 
 
 
Mutations outside the Ca2+-binding motifs - ΔSLQ, V100D and D122V 
The observed Tm value of 34 °C for the nonsense mutation that results in deletion of the last 
three amino acids of MCFD2 (ΔSLQ) suggests that this C-terminal truncation causes severe 
destabilisation of MCFD2. These deleted residues are part of the core of the MCFD2 structure 
and NMR data show that they are involved in a large number of long-range NOE interactions. 
It is therefore not surprising that their removal has severe consequences for the integrity of the 
structure of MCFD2.  
The mutation V100D is not a confirmed disease-causing mutation, but is found in a 
heterozygous state together with D81H in a homozygote state. The thermal melting profile for 
V100D, yielding a Tm value of 44 °C, demonstrates that this mutation causes destabilisation of 
MCFD2. In the NMR structure of un-complexed MCFD2 the side chain of V100 packs tightly 
with other hydrophobic residues and contributes to the hydrophobic core. Substitution of this 
valine with a charged aspartate probably disrupts the packing of the hydrophobic core and has 
a destabilising effect. Hence, this mutation cannot be ruled out as cause of F5F8D, although the 
mutation D81H, which leads to an essentially unfolded protein, is most likely the main cause in 
these patients.   
In contrast to the other F5F8D causing mutations that result in a disordered or 
destabilised protein, CD analysis of the mutation D122V results in a spectrum and Tm value 
identical to wild-type MCFD2 (figure 18), thus implying a fold and stability characteristic of 
the wild-type protein. Positioned in the middle of the third -helix, which is tilted towards 
ERGIC-53 upon complex formation, D122 contributes strongly to the binding of ERGIC-53 by 
an ionic interaction with K49 and a hydrogen bond to Y48 on ERGIC-53. In light of this, it is 
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not surprising that substitution of this aspartate with a valine severely affects binding to 
ERGIC-53 and as a consequence causes F5F8D.  
 
In summary, the results from these studies clearly emphasise the importance of intact calcium 
binding EF-hand motifs for the structural stability of MCFD2. This is demonstrated by the fact 
that all, except one, of the missense mutations reported to date are localised within these 
motifs, and that they give rise to a disordered or severely destabilised MCFD2 protein. None of 
the characterised mutations can be directly implicated in cargo binding of FV and FVIII. 
Instead our results suggest disruption of the ERGIC-53/MCFD2 interaction as the underlying 
mechanism for these mutations in causing F5F8D.  
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3.4 Oligomerisation properties of ERGIC-53  
 
The influence of oligomerisation on ER export efficiency has been studied in detail for 
ERGIC-53 (Lahtinen et al. 1999, Nufer et al. 2003, Neve et al. 2005). From these studies a 
mechanism has been proposed in which lumenal and transmembrane determinants mediate the 
oligomerisation of ERGIC-53 required for its recruitment into budding COPII vesicles via the 
C-terminal di-hydrophobic motif. In these events two membrane proximal cysteines (C466 and 
C475) have been found to be important in the formation of disulfide-linked oligomers of 
ERGIC-53. Recent data have confirmed their significance and suggested that ERGIC-53 can 
exist in two homo-hexameric forms: the first composed of a covalent disulfide-linked hexamer 
and the second consisting of three disulfide-linked dimers assembling into a non-covalent 
complex (Neve et al. 2005). Moreover, it has been shown that the transmembrane domain 
mediates hexamerisation of ERGIC-53 and this has been proposed to be a prerequisite for the 
oligomerisation (Nufer et al. 2003). Recent data has also indicated the presence of a third 
structural determinant, within the four predicted α-helices of the stalk domain, to be involved 
in and promote oligomerisation (Neve et al. 2005).  
In order to investigate the oligomerisation properties of ERGIC-53 within a structural 
context protein constructs coding for the full-length lumenal part of the protein, the CRD with 
alternative end points of the stalk domain and the isolated stalk domain were generated and 
expressed in E. coli. Two of these constructs, the CRD including two predicted α-helices of the 
stalk domain (CRD-2H) and the isolated stalk domain (figure 19), could be further 
characterised by size-exclusion chromatography (SEC), CD spectroscopy and polyacrylamide 
gel electrophoresis (PAGE). Characterisations of the other constructs were hampered by low 
yield and low solubility. 
 
 
 
 
Figure 19. (A) Schematic representation of 
the structural organisation of ERGIC-53, the 
carbohydrate recognition domain indicated as 
an oval (CRD), the predicted helices (I, II, III 
and IV of the stalk domain) and the 
transmembrane domain (TM) as squares. The 
two conserved cysteine residues (C466 and 
C475) and the transport determinants of the 
cytoplasmic domain are highlighted. 
Truncated constructs used in the study, (B) the 
isolated stalk domain, and (C) CRD-2H, the 
CRD and the two proximal helices.   
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3.4.1 Evidence for disulfide-bond independent oligomerisation 
 
A 
 
M w standard
Pro t ein  kDa ml
Blue dextran .void 45,4
Ferret in .440 54,7
Catalase .232 63,7
Albumin .67 74,2
Ovalbumin .43 81
Chymotrypsinogen A .25 90,5
Ribonuclease A  .13,7 96,2
 
B                                                          C                
 
Figure 20. (A) The oligomeric states of the construct CRD-2H (Mw 43279.2 Da) analysed by SEC on a 
Superdex 200 10/300 column. Apparent elution volume, molecular weights and classification of eluted 
oligomers have been indicated. (B) SDS-PAGE gel analysis of SEC, stained by Coomassie blue with 
molecular weight of marker indicated to the right. Lane 1, S- sample before SEC, followed by analysed 
fractions, H-hexameric CRD-2H, 60-66 ml , D-dimeric CRD-2H, 68-72 ml and *CRD, 90 ml. (C) 
Native PAGE gel analysis of pooled  fractions corresponding to H-hexameric and D-dimeric CRD-2H. 
* CRD of ERGIC-53 (~25 kDa) - proteolytic degradation product from expression in E. coli.  
 
During SEC the CRD-2H variant eluted as two distinct oligomeric species with apparent 
molecular masses of approximately 250 kDa and 80 kDa (figure 20a), which correspond to the 
hexameric and the dimeric states of CRD-2H. Native PAGE analysis confirmed the presence of 
two oligomeric species and also indicated some dynamic exchange between the two species 
(figure 20c). Thus, although missing the known determinants contributing to the 
oligomerisation, the transmembrane region and the two cysteine residues involved in disulfide 
bond formation, assembly of oligomers was apparent.  
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Figure 21. Far-UV CD spectra of the SEC elution fractions of CRD-2H corresponding to the dimeric 
state (continuous line) and the hexameric state (dotted grey line). 
 
Since an unfolded protein is expected to migrate at a higher molecular weight during SEC and 
native PAGE we wanted to ensure that the two oligomeric species of CRD-2H were properly 
folded. To address this issue far-UV CD spectroscopy was performed on the eluted fractions 
from SEC corresponding to the two oligomeric species. The CD spectra confirmed both 
oligomeric species to be properly folded, showing contribution predominantly from β-sheet 
secondary structure, but with evident contribution from α-helical secondary structure (figure 
21). Although clearly folded the two oligomeric species show slightly different spectrum 
profiles, indicating differences in secondary structure composition between the dimeric and 
hexameric species.  
 
 
3.4.2 Oligomerisation properties of the isolated stalk domain 
In addition, the oligomerisation properties of the isolated stalk domain were investigated by 
characterising a construct containing the four putative helices and the two membrane proximal 
cysteins of this domain. The CD spectrum of this construct showed a predominant contribution 
from α-helical secondary structure, confirming previous predictions (figure 22a). 
Glutaraldehyde cross-linking under non-reducing conditions in conjunction with SDS-PAGE 
analysis of this construct revealed the formation of a higher molecular weight species 
corresponding to a hexameric complex (figure 22c). However, upon SDS-PAGE analysis of 
non-cross-linked protein, this complex dissociates into dimers and under reducing conditions 
into monomers (figure 22b). Mass spectrometry analysis further confirmed the presence of a 
complex consisting of reduction-sensitive disulfide linked dimers by detecting the mass 
corresponding to the dimer (47699.4 Da) (figure 22d) under non reducing conditions and after 
reduction with DTT the mass of a monomer (23853.0 Da) (figure 22e).  
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Figure 22. Characterisation of the ERGIC-53 stalk domain (Mw 23853.2). (A) Far-UV CD spectra 
collected under native conditions. SDS-PAGE gels, stained by Coomassie blue with molecular weight 
of marker indicated. (B) lane 1, Marker, lane 2 native stalk domain, and lane 3, after reduction with 
DTT. (C) Glutaraldehyde cross-linking performed under native condition: lane1, marker, lane 2, before 
addition of glutaraldehyde, followed by lanes 3-5 representing samples collected at different time points 
after addition of glutaraldehyde. Mass spectrometry analysis of the ERGIC-53 stalk domain, (D) before 
and (E), after reduction with DTT (The detected masses are within 3 Da of the expected values).  
 
This data is consistent with previous findings which have shown that one of the oligomeric 
species of ERGIC-53 exists as SDS-sensitive complex of disulfide-linked dimers. However, 
the reported complex consisting of a covalently disulfide-linked hexamer shown to exist in vivo 
on studies performed on wild-type ERGIC-53, was not detected in this study. This suggests 
that the lumenal stalk domain alone is not able to form this complex, or that expression in E. 
coli does not enable the formation of the disulfide-linked hexamer.  
 
In summary, this study demonstrates that the truncated version CRD-2H of ERGIC-53, without 
the transmembrane region and the two membrane proximal cysteine residues, is able to 
assemble into hexamers. Hence, this strengthens the evidence for the involvement of the stalk 
domain in the oligomerisation of ERGIC-53 and highlights the importance of the two helices 
closest to the CRD. However, it cannot be ruled out that the oligomers formed by this truncated 
  43
 
 
protein variant could be artefacts and further studies are required to determine if the oligomeric 
species observed in this study correspond to the native forms.  
In addition, the expression of the isolated stalk domain in E. coli resulted in a non-
covalent complex of three disulfide-linked dimers. The absence of the covalent disulfide-linked 
hexamer in this study might reflect that formation of this complex requires additional factors or 
an environment other than that provided by the E.coli expression machinery. An interesting 
theory proposed by Neve et al. is the existence of an ER or ERGIC localised disulfide 
isomerase catalysing re-arrangement of disulfide bonds, and thus acting as a reversible switch 
between the two disulfide-linked complexes (Neve et al. 2005). Although plausible, no 
evidence for such mechanisms exists thus far. Interesting challenges for future studies will be 
to clarify the mechanism and role of the different disulfide-linked ERGIC-53 complexes in 
cycling and cargo transport processes between the ER and the ERGIC. Furthermore, it will be 
of high interest to reveal if binding of cargo proteins or any post-translational modification, 
other than disulfide bond formation, influences the oligomeric organisation of ERGIC-53. 
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3.5 ERGL, a regulator of the ERGIC-53/MCFD2 complex? 
 
ERGL was first identified in prostate tissue and its expression has been found to be restricted to 
specific tissues including prostate, spleen, salivary gland, cardiac atrium and cells of the central 
nervous system (Yerushalmi et al. 2001). The first 230 amino-terminal residues of the 
expressed protein show high homology to the CRD of the family of L-type lectins. Particularly, 
the CRD of ERGIC-53 shows high sequence identity to ERGL (51%) (figure 23a). 
Interestingly though, ERGL is missing a number of key residues which have been found to be 
critical for calcium- and sugar-binding in ERGIC-53 and the other animal L-type lectins (figure 
23b). Furthermore, ERGL lacks typical transport motifs in the cytoplasmic tail that are found in 
ERGIC-53, and is predicted to be ER resident. Although ERGL has a different expression 
pattern compared to the ubiquitously expressed ERGIC-53 and is confined to the ER, the 
predicted domain organisation is highly similar between these two proteins. While several 
proteins have been found to interact with ERGIC-53, and it has been shown to form a 
glycoprotein transport complex with MCFD2, the function of ERGL remains to be revealed. 
 
 
 
Figure 23. Sequence conservation between the CRDs of ERGIC-53 and ERGL. Conserved amino acids 
colored dark grey and non-conserved in light grey. (A) Structure of the ERGIC-53 CRD in complex 
with MCFD2. (B) A close-up view of calcium and putative carbohydrate binding residue in ERGIC-53 
with residues shown as sticks, labelled, and with the corresponding residue found in ERGL denoted for 
non-conserved residues.  
 
In order to shed light on the role of ERGL in the secretory pathway constructs including full-
length human ERGL, the luminal part of it, and the isolated CRD and the stalk domain were 
generated. Of these constructs, the isolated stalk domain could be expressed and by using CD-
spectroscopy this domain was shown to mainly consist of α-helical secondary structure as 
predicted by bioinformatics. Characterisation of the other constructs was hampered by low 
yield and low solubility.  
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3.5.1 ERGL/MCFD2 interaction analysis  
The MCFD2-binding site of ERGIC-53, which primarily consists of the loop connecting the β1 
and β2 strands, is not conserved within the L-type lectin homologues VIP36 and VIPL. SPR 
analysis has confirmed that neither VIP36 nor VIPL bind to MCFD2, despite the structural 
similarities of their CRDs to ERGIC-53 (Kawasaki et al. 2008). However, thus far no studies 
have probed an interaction between MCFD2 and ERGL. Interestingly, the MCFD2-binding site 
in ERGIC-53 is conserved within the ERGL CRD. We hypothesise that this region of ERGL 
could bind MCFD2 in a manner similar to that of ERGIC-53 and form a complex. To address 
this hypothesis we investigated the binding of MCFD2 to this region by NMR spectroscopy 
and biolayer interferometry using a set of three synthesised peptides of 13 residues each, 
mimicking this region in ERGIC-53, ERGL and VIP36, respectively (figure 24).  
 
A 
 
B 
          45           55           65          75          85 
ERGIC-53  PHRRFEYKYSFKGPHLVQSDGTVPFWAHAGNAIPSSDQIRVAPSLKSQR  
ERGL      PLRRFEYKLSFKGPRLALPGAGIPFWSHHGDAILGLEEVRLTPSMRNRS  
VIP36     --EHLKREHSLIKPYQGVGSSSMPLWDFQGSTMLTSQYVRLTPDERSKE  
 
Figure 24. (A) The interface between MCFD2 (grey) and ERGIC-53 (dark grey). Hydrogen bonds are 
shown as dashed lines and interacting residues are shown as sticks and labelled. (B) Sequence 
alignment with light grey shading representing identical residues found in ERGIC-53 and ERGL, and 
identical residues also found in VIP36 shown with black background and white text. Boxed residues 
correspond to the synthesised peptides of 13 residues used in this study.  
  
NMR analyses using 15N-labeled MCFD2 show coordinated chemical shift changes in the 15N-
HSQC spectra upon addition of the ERGL and ERGIC-53 peptides, whereas the chemical shift 
perturbation for the VIP36 peptide is much less pronounced (figure 25a). Although these 
results give a strong indication that MCFD2 interacts with a similar binding mode to, ERGIC-
53 and ERGL, further studies are required to support this theory. A major drawback in this 
study was that spectra had to be collected in different buffer conditions than those of the 15N-
HSQC spectrum used as reference in previous experiments, due to aggregation of the peptides. 
This resulted in limited applicability of our previous chemical shift assignments. In order to 
proceed with this study, a new set of assignment experiments would therefore be of highest 
interest.  
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A                                                                        B 
 
 
Figure 25. Interaction analysis. (A) Chemical shift perturbation data from, 15N-HSQC spectra upon 
mixing 15N-labelled MCFD2 and the peptides: ERGL-CRD(RRFEYKLSFKGPR) (black), ERGIC-53-
CRD(RRFEYKYSFKGPH) (grey) and VIP36-CRD(EHLKREHSLIKPY) (white), respectively. Data 
were calculated for each of the 26 residues that could be assigned, using the equation (0.04δN2+δH2)1⁄2 
(ppm), where δN and δH represent the change in nitrogen and proton chemical shift. (B) Biolayer 
interferometry sensorgrams of binding to MCFD2 for each of the peptides used in the NMR analysis 
monitored at a concentration of 100 μM. The affinities of the ERGL-CRD and ERGIC-53-CRD 
peptides to MCFD2 were calculated using a 1:1 binding model. 
 
Real time binding assays between biotinylated MCFD2 captured on a surface of streptavidin 
and peptides in solution were performed using biolayer interferometry (figure 25b) 
(OctetRedsystem). The association and dissociation of each peptide to MCFD2 was monitored 
and from this data KD values in the low micromolar range could be determined for the ERGL 
and ERGIC-53 peptides to MCFD2. No interaction could be detected between the VIP36 
peptide and MCFD2 confirming previous findings (Kawasaki et al. 2008).    
 
In summary, this study strengthens the hypothesis that ERGL forms a complex with MCFD2, 
although the role of this complex still remains elusive. To date, MCFD2 has been directly 
linked only to the function as a co-receptor for ERGIC-53 in the transport of the coagulation 
factors FV and FVIII. However, MCFD2 has been shown to maintain stem cell potential in the 
adult central nervous system and is recognised as a marker for testicular germ cell tumours 
(Toda et al. 2003, Gashaw et al. 2007). Interestingly, the tissue-specific distribution of ERGL 
is coincident with these yet unresolved processes in which MCFD2 is overexpressed. Although 
highly speculative, the ER resident protein ERGL could function as regulator of the ERGIC-
53/MCFD2 complex by interacting with MCFD2 in the ER and by this means indirectly 
control secretion of glycoproteins. It will be highly interesting to learn the function of ERGL 
and the dual function of MCFD2, if there is one, when they are revealed. 
  
  47
 
 
4 CONCLUSIONS 
 
Within this thesis work, NMR spectroscopy and X-ray crystallography have been applied to 
elucidate the organisation and function of the ERGIC-53 /MCFD2 glycoprotein transport 
receptor complex. The work resulted in the three-dimensional structure of MCFD2 in solution 
determined by NMR and the crystal structure of MCFD2 in complex with ERGIC-53-CRD. 
The combination of the two techniques for structural characterisation provided unique insights 
into the mechanisms of the interaction between these proteins.  
NMR studies of MCFD2 revealed that the protein is disordered in the absence of Ca2+ 
ions and adopts a predominantly ordered structure upon binding Ca2+ ions. Hence, this work 
not only resulted in the first three-dimensional structure of MCFD2, but also gave insights into 
the mechanism by which Ca2+ functions as an allosteric regulator on MCFD2 binding to 
ERGIC-53. Furthermore, from CD and NMR analysis the consequences of all known F5F8D 
causing missense mutations found in MCFD2 could be explained. The results highlight the 
importance of intact calcium binding EF-hand motifs for the structural stability of MCFD2 and 
point toward disruption of the ERGIC-53/MCFD2 interaction as the underlying mechanism for 
these mutations in causing F5F8D.  
The crystal structure of ERGIC-53-CRD/MCFD2-ΔN complex gave a first molecular 
view of the organisation of a cargo receptor complex in the early secretory pathway. Moreover, 
the structure revealed that MCFD2 undergoes significant conformational changes upon 
complex formation, which results in the exposure of its hydrophobic core. Although it has yet 
to be proven, the structural changes observed in MCFD2 could be part of the mechanism 
regulating the interaction between the receptor ERGIC-53/MCFD2 complex and the cargo 
proteins FV and FVIII. Overall, this thesis work has provided new insights into the structural 
organisation and function of the ERGIC-53/MCFD2 transport complex. From this, a whole 
new set of questions and challenges for future studies has emerged. 
 In order to fully understand how the ERGIC-53/MCFD2 complex recognises and 
transports cargo, a key objective will be to determine how the oligomeric states of ERGIC-53 
influence these processes. The preliminary data described in this thesis have strengthened the 
evidence for that disulfide bond formation, along with interactions between the α-helices 
within the stalk domain, are involved in the assembly of ERGIC-53 into hexamers. However, 
the exact organisation of this hexamer still remains elusive and will be of high interest for 
future studies to reveal. Moreover, preliminary data suggests that ERGL, the closely related ER 
resident homologue of ERGIC-53, interacts and forms a complex with MCFD2. Although the 
role of this complex remains poorly understood, one could imagine a scenario where ERGL 
functions as regulator of the ERGIC-53/MCFD2 complex in the ER by interacting with 
MCFD2. 
 
In summary, this thesis work has provided new information on the organisation of receptor 
mediated transport in the secretory pathway. The combination of methods for structural 
characterisation, such as X-ray crystallography and NMR spectroscopy, applied in this thesis 
will be a key approach in the future to elucidate the structures and assembly dynamics in the 
myriad of complexes that exist in the secretory pathway.  
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